annual repor c r n g comforts fulfills heals touches empowers transforms inspires endures cover around world focused making lifechanging longterm differences prevention treatment hivaids hiv franchise continues grow discover develop provide access medicines like prezista darunavir intelence etravirine involvement communitybased programs mothersmothers south africa continues touch lives read hivpositive mentor mother kangela sonwho hivnegativein story chairmans letter shareholders men women johnson johnson come work day driven shared passion caring caring touches lives people around world motivates us identify unmet health care needs reach increasing numbers patients consumers create broader solutions serious medical conditions also general health william c weldon wellbeing worlds population chairman board directors chief executive officer caring empowers others touches patients patent expirationseven faced unanticipated deteriora consumers across world inspires hope grounded tion global economy fundamental tenets credo decentralized worldwide sales grew billion increase percent management approach keeps people close operational growth percent achieved strong adjusted customers markets drove business success earnings growth percent adjusted earnings per share mobilizes us capitalize new health care opportu growth percent higher adjusted earnings net sales nities meet challenges ahead unprecedented growth due sharerepurchase program free cash flow difficult gdloiblualt eecdon eomarinc sinetgtisn gper share strong approximately billion dividends paid per share growing businesses also took thoughtful highlights remember year extraordinary disciplined actions streamline improve cost structure economic events shook financial markets global econ within pharmaceuticals cordis businesses approximately omies backdrop proud accomplishments billion annual savings realized anticipate johnson johnson delivered financial commitments additional savings standardization initiatives driven strength broad base human health care busi invested time nesses achieved results despite anticipated market meanwhile remain track fulfill potential challengessuch increased generic competition worldwide pfizer consumer healthcare acquisition expecting meet net sales diluted earnings per share dividends paid per share billions dollars dollars dollars chairmans letter exceed target million turbulent hiv combination therapy stelara million cost synergies expect ustekinumab approved canada economic times transaction breakeven eu treatment moderate modestly accretive year one year johnson johnson severe plaque psoriasis ustekinumab ahead original schedule thirdbest currently review fda types actions drove gains medical devices diagnostics performing stock adjusted segment operating profit pipeline strong new products billion percent sales dow jones industrial entries new markets example compared billion average share ethicon endosurgery inc introduced percent sales teams harmonic combination hook blade holder returns excellent job improving margins even harmonic synergy curved blade volatile economic climate began one three five taking minimally invasive surgical driving increases commodity costs tenyear periods instruments proven clinical value shifts consumer patient behaviors strong intellectual property orthopae exceeded major also continued billion dic plastic surgery new specialties sharerepurchase program comparative indices company yearend purchased approximately vision care franchise continued billion stock fifth year solid growth acuvue turbulent economic times worlds widely prescribed contact johnson johnson third lens brand launched two new products bestperforming stock dow jones acuvue oasys brand contact lenses industrial average shareholder returns one three astigmatism introduced united kingdom day five tenyear periods exceeded major comparative acuvue trueye worlds first daily disposable silicone indices delivering financial results cost structure hydrogel contact lens improvements investing businesses sus developing core businesses also expanded tained growth made significant strides toward strengthening new markets acquisitions johnson johnson acquired market positions areas compete today mentor corporation leading supplier medical products identifying new highgrowth opportunities broadening global aesthetic market acquisition provides ethicon capabilities trillion health care market franchise opportunity grow aesthetic reconstruc continue deliver four major business priorities tive medicine raising standard innovation patient remain fundamental longterm growth outcomes believe mentor become cornerstone winning health care broader johnson johnson leadership strategy aesthetic capitalizing convergence medicinea highgrowth market serving consumers accelerating growth emerging markets medical professionals developing leadership talent winning health care also means going beyond trillion market businesses compete today finding growth winning health c winning health care requires multi opportunities broader trillion health care market pronged approach longterm success accordingly continue office strategy growth charged mission invest internal development pursue selective licenses initial step creation wellness prevention acquisitions meanwhile thoughtfully navigating business platform johnson johnson made two acquisitions competitive industry challenges affecting global health care began laying groundwork new business research development remained strong billion healthmedia inc offers suite interventions provide driven strong science unmet patient needs personalized webbased coaching wellness disease manage advanced pipelines ment behavioral health medication adherence proven last year one productive pharmaceuti outcomes improved compliance reduced medical utilization cal pipeline terms filings approvals positive regulatory increased productivity meanwhile human performance opinions pipeline diverse wellbalanced bio institute developing sciencebased training programs pharmaceuticals small molecules covering therapeutic areas improve employee health wellness expect new business high unmet needs sustained research productivity contribute performance workforces products track complete filings seven new products services keep employees healthy engaged productive beginning end building businesses also actively participating well meet target set back public policy discussions around world given breadth latestage pipeline robust eight new compounds businesses longstanding reputation often called currently registration five filed upon perspectives always focus remains us food drug administration fda nucynta consumer patient preserving access care incentives tapentadol immediaterelease tablets relief moderate innovation severe acute pain adults age older granted fda johnson johnson uniquely positioned thrive approval regulatory authorities canada european union rapidly changing health care landscape blend industry eu us approved intelence etravirine perspectives consumer insights scientific innovation finan johnson johnson annual reportcial strength provides us uniquely research providers local market insights prod strong base present future growth ucts strategies development three components core capitalizing c onvergence remained strong emergingmarkets strategy first future breakthrough innovation lies billion training health care professionals capitalizing convergence products provide optimal patient care opened driven technologies patientcentric solutions professional education center beijing power johnson johnson strong science conjunction olympic games enterprise broad base businesses unmet patient needs sponsorship also established working together creates distinctive professional education center russia advanced competitive advantage diverse meanwhile vision care institute llc capabilities expertise talent financial pipelines providing important training infor strength enable us develop innovative mation eye care diverse cities solutions advance health care around including shanghai dubai bangkok world build longterm success plans continue global expansion johnson johnson launched johnson johnson good collaborative thinking leads diabetes institute llc four global important new products fibrin pad markets developed jointly scientists ethicon professional education centers across inc centocor inc along omrix world biopharmaceuticals inc combines mechani second continue build local cal biological action advanced hemostasis reducing surgery capabilities fully integrate market people time need blood transfusions johnson johnson official health care sponsor beijing olympic acquired omrix biopharmaceuticals late paralympic games company businesses built lasting capabilities area bond chinese people opening opportunities sustained companies comprise diabetes care franchise business growth recruitment best talent local capabili creating full range solutions empower patients ties enhanced acquisition beijing dabao technology education services new product introductions cosmetics co ltd maker wellknown respected skin care allow patients consistently monitor blood glucose levels brand china first significant acquisition mar discreetly administer insulin also acquired two online ket additionally began manufacturing new orthopaedic communitieschildren diabetes inc spanish facility suzhou china emerging market innovation language diabetes juvenilto help connect families virtually center shanghai develops products emerging markets also johnson johnson diabetes institute llc brings together gathers indepth insights chinese consumer diverse medical professionals common goal improving finally developing number marketappropriate outcomes people diabetes products endosurgical instruments sutures baby capitalizing power scope johnson johnson care products better meet local needs enterprise also source competitive advantage busi nesses launch zyrtec cetirizine hcl sale without developing leadership alent well prescription united states successful product positioned longterm growth strategies remain launch also marked largest prescription passionate people johnson johnson inspired thecounter otc switch company history zyrtec credo teams overcome daily competitive challenges launch demonstrated unique advantage quests discover new ways improve health care satisfy consumer pharmaceuticals businesses work together unmet needs open new markets combine strong consumer marketing expertise indepth professional development people remains top knowledge managedcare market priority operating companies around scientists marketers continue develop convergent world capability develop leaders exposing personalized health care solutions highgrowth areas wide variety businesses everincreasing responsibility skin care obesity oncology cardiology potential allow take prudent risks enhance making impact standards care categories judgment businessbuilding capabilities focus leader tremendous believe breadth johnson johnson ship development ensures smooth succession makes us uniquely able seize opportunities lie ahead senior management levels addition making excellent progress business accelerating growth emer ging markets one priorities throughout achieved sustained results largest growth opportunities rests emerging global markets business segments driven solid management teams brazil russia china india rapidly developing coun dedicated employees tries turkey mexico also showing solid growth johnson johnson maintained significant wellestablished consumer health c consumer health care business presence markets decades utilizing decentralized delivered strong growth sales billion operating model stay close patients consumers health care total growth rate percent growth drivers included chairmans letter otcnutritionals business led zyrtec johnson johnson devices offer surgeons greater func skin care brands led aveeno clean tionality flexibility diverse surgical uniquely positioned clear neutrogena listerine procedure requirements thrive rapidly antiseptic mouth rinse international acquisition mic ab privately held sales baby care products dabao changing health care swedish developer vitro diagnostics leading moisturizer china also contrib orthoclinical diagnostics inc access landscape blend uted growth new delivery channels pointofcare industry perspectives consumer business continues nearpatient settings outside history strong revenue operating consumer insights clinical laboratory profit growth maintain solid leadership businesses introduced several new scientific innovation posi tions positions products strengthened pipelines financial strength nine major categories sustain future growth depuy orthopaedics compete provides us inc introduced trilock bone focus superior science differen preserving hip stem proprietary uniquely strong base tiates us competitors builds gription technology stability present future longterm advantage science deep maintaining leading position consumer insights catalysts behind growth hip replacement us market growth strategies include organic europe lifescan inc launched new growth iconic brands focus new onetouch vita blood glucose meter ventures commitment emerging particularly beneficial people type market development diabetes find disease complex across franchises clinical trial design analysis difficult manage convergence accurate reliable critical competencies new products innovative new easytouse technology patient insights preferred claims strong network professional relationships sizes shapes colors onetouch ultramini blood supported science built many brands glucose meter become selling blood glucose meter place professional recommendations united states united states international markets tylenol johnsons baby given competitive strengths mdd businesses neutrogena listerine neosporin opportunities growth remain enthusiastic brands trustedand highly recommendedby potential sustained longterm growth segment medical professionals around world pharmaceuticals pharmaceuticals businesses ended medical devices diagnostics medical devices year sales billion representing total decrease diagnostics mdd franchises continue comprise percent versus prior year breadth depth worlds largest medical technology business sales growing product portfolio enabled us lessen impact billion total increase percent prior year generic competition risperdal risperidone slower growth driven minimally invasive products disposable sales procrit epoetin alfa contact lenses orthopaedic sports medicine products nine products sales billion growth medical technology market offers significant growth driven strength currently marketed products fueled opportunities light aging demographics unmet medical cases new indications others approvals needs technological innovation addition see low additional markets penetration rates many key categories along growth products included velcade bortezomib geographic development opportunities wellpositioned received european commission approval previously capitalize market potential positions untreated multiple myeloma remicade infliximab majority markets compete biologic approved treatment number immune opportunities particularly solid markets mediated inflammatory diseases topamax topiramate ophthalmology cardiology metabolic disease treatment epilepsy migraines hiv franchise strong need patientcentric solutions address chronic disease european commission approved oncedaily dosing within area comprehensive care group charged mg prezista darunavir lowdose ritonavir part developing novel approaches care across entire continuum combination therapy treatmentnave adults disease delivering costeffective outcomes meanwhile never taken hiv medication approval broadens surgical care group focuses developing surgical businesses previous indication darunavir treatmentexperienced new technologies solutions support patients beyond hiv patients means prezista used time surgical intervention full spectrum hivaids patients eu member states mdd businesses achieved several significant milestones antipsychotic franchise invega paliperidone addition mentor corporation omrix oncedaily atypical antipsychotic risperdal consta biopharmaceuticals strategic acquisitions several risperidone longacting injection continued grow companies strengthened pipelines ethicon endosurgery inc filed additional indication risperdal consta acquired surgrx inc bringing together companys enseal frequently relapsing bipolar disorder us new indica products harmonic line ultrasonic medical tions existing products included concerta methyl johnson johnson annual reportphenidate hcl extendedrelease tablets around world tant confident people adult attention deficit hyperactivity disorder around world people bring people bring adhd doribax doripenem passion caring work every day passion caring injection eu urinary tract perhaps greatest reason infections intraabdominal infections work every day enduring success day people nosocomial pneumonia infection remind caring extraordinary perhaps latestage pipeline also promising motivator overcomes many chal greatest reason poised several potential lenges todays health care environment launches rivaroxaban enduring difficult economic times codeveloping bayer healthcare ag browse stories fol success united states initially development lowing pages see prevention deep vein thrombosis inspires people johnson johnson pulmonary embolism patients undergoing added stories countless hip knee replacement surgery works throughout company also encouraged paliperidone palmitate great science deep insights longacting injectable antipsychotic patients consumers innovative monthly dosing market approaches dedication addition concentrating rd corporate citizenship people bring productivity carefully navigating new definition caring inspired challenging regulatory reimbursement credo reminds us environments growing competition company believe generics combined focus remain confident operating modelbroadly based human health care pharmaceutical pipeline introduce new better solu decentralized approach managed long term tions unmet medical needs focused people valuesimpels us find best possible solutions todays pressing health care needs focus commitment growth unprecedented technologies passed generation generation employees aging populations strong emerging markets powerful johnson johnsonall share inspiration caring consumers creating number new opportunities remains hallmark businesses maintain clear strategy pursuing future growth evident progress made commitment achieved solid entered unusually challenging period progress growth strategies strengthened core facing global financial business slowdown unlike anything franchises advanced pipelines introduced new products seen lifetimes sustain revenue growth invested new opportunities every challenging period brings corresponding fuel robust future growth maintained strong balance sheet opportunity growth exception working allows us capitalize emerging opportunities disciplined way johnson johnson emerge stronger future continued operate business model ever believe several reasons delivers sustained results led inspired people fortunate experienced management team take ingenuity caring new levels reasons place right skills capitalize market conditions remain confident johnson johnson continue grow build businesses longterm growth stronger years ahead delivering superior levels strengthening core franchises advancing pipe performance benefit patients consumers medical profes lines introducing new products replenish grow sionals employees communities loyal shareholders revenue streams building market leadership positions venturing new growth spaces johnson johnson maintaining financial strength flexibility william c weldon combination strong cash flows aaa credit rating chairman board directors chief executive officer gives us access credit favorable rates implemented cost structure improvements march reap benefits bottom line help us operate efficiently actively participating dialogues public policy shape business environment years come excludes inprocess research development special items whenever economy health care markets return see reconciliation nongaap financial measures robust growth stronger betterpositioned lead free cash flow defined operating cash flow less capital spending ership markets adjusted segment operating profit incomeexpenses allocated segments excludes inprocess research development commitment caring confident growth special items see note consolidated financial statements johnson johnson many reasons perhaps impor reconciliation nongaap financial measures chairmans letter caring transforms surgeons care children vision use harmonic technology w fred hess md treats cornerstone growing energy franchise offer multiple benefits surgeons patients procedure says scoliosis spinal hedy hashemi ethicon endosurgery marketing director deformities uneven responsibility harmonic line one harmonic surgical device waist asymmetrical shoulders large hump ethicon endosurgery acquired technology today great pain theyre barely harmonic product line comprises devices including seven products launched sixmonth period able walk intricate surgery dr hess november april energy franchise performs last hours often gained another platform acquisition surgrx inc makers enseal devices seal large vessels requires transfusions due major blood loss surgery patients go football tennis swimming diving champions makes day week year winning ouchdown dr hess longtime user surgical says dr hess chief spine section department orthopaedic products depuy spine inc operates latest harmonic surgery geisinger medical center danville pa devices surgeries continue touch lives dr hess began using two new surgical devices offduty performs surgery children ecuador harmonic combination hook harmonic synergy ghana barbados several countries wife heather curved blade latest innovations harmonic energy son andy daughter ashley college student ethicon endosurgery inc take proven technology volunteer firefighter emthave joined dr hess trips orthopaedic plastic surgery new specialties distribute food medicine also brings children geisinger ethicon endosurgery another device launched medical center treatment including bosnian boy ergonomically enhanced harmonic ace curved shear injured landmine explosion honduran girl easytouse handle laparoscopic procedures becoming paraplegic due tuberculosis spine whats unique harmonic technology uses hour surgery walk ultrasonic energy simultaneously cut coagulate tissue avid football fan plays hospital team dr hess surgery benefits traditional scalpel electro also volunteers physician danville high school surgery techniques include minimal thermal tissue damage ironmen football team one day spotted offensive tackle patient precise cutting surgeon well looked familiar realized operated teen fewer instrument exchanges cases seems impact boy broke back car accident recovery process says dr hess makes difference allstate champion though player opposing team care provide patients dr hess heart swelled wonderful make difference someones life says energy platform drives growth harmonic devices tools transform w fred hess md chief spine used worldwide million open section department orthopaedic surgery geisinger medical laparoscopic procedures including general gynecological center danville pa began using two new surgical devices bariatric colorectal surgeries feedback hundreds latest innovations harmonic energy surgeons regularly perform procedures continues ethicon endosurgery inc says dr hess makes play important part developing devices difference care provide patients johnson johnson annual report johnson johnson annual report corporate level revisions pm surgical care johnson johnson annual report corporate level revisions pm surgical carejohnson johnson annual report corporate level revisions pm surgical careour caring delivers personalized skin care c herie price says used selfconscious face breaking actor frustrating says los angeles resident dont want worry people judging face cherie tried years find right acne treatment available exclusively wwwskinidcom hotline drugstore shelves offered many options never knew skin id uses proprietary dermatologist choose tried werent right developed skin evaluation result personalized regimen found skin id neutrogena corporation consisting three products cleanser two products first personalized acne solution thats based individuals hydrator antiacne treatment toner skin lifestyle moisturizer neutrogena one johnson johnson consumer takes steps define acne problems businesses scientists sought way personalize skin care says cherie describing free skin id evaluation persons acne treatment would meet wwwskinidcom liked lot personalized particular needs skin id regimens tested randomized double realized could create way hear blind placebocontrolled study industryleading acne person needs lifestyle preferences could treatments five hundred participants treated eight deliver effective personalized solution says bobby sheikh weeks results spectacular says sheikh could launch product director skin id stores see improving peoples lives generally arent equipped help people personaliza felt amazing couldnt stop looking mirror says tion process developed products distribution model cherie results lifechanging experience sells skin id product line directly consumers saw face change better taking skin care personally los angeles actor cherie price says face calling card acne giving wrong impression found skin id neutrogena corporation first personalized acne solution thats based individuals skin lifestyle changed complexion skin life says caring embraces many johnson johnson consumer johnson johnson family companies brands part peoples daily health since acquisition access trusted hygiene rituals around world greater marketing resources weve le petit marseillais trusted family able accelerate plans expand brand brand year heritage leads additional markets says eric panijel french market personal cleansing general manager laboratoires vendme part strategic acquisition groupe also benefit research capabilities vendme johnson johnson sa france fuel innovative product development french advertisement new enhanced johnson johnson average new le petit le petit marseillais orange blossom adult baby skin care businesses marseillais products launched shower gel father son encounter tree year percent french house year new orange blossom covered orange blossoms south holds buy least onel e petit marseillais shower gel quickly became one france scent reminds father shower gel soap bath hair care product top three shower gels france met fell love boys products promote wellbeing lighthearted ad helps mother reminiscence interrupted emphasize beneficial ingredients found brands heritage panijel says le petit boy remarks smell makes nature le petit marseillais enjoying marseillais special place think shower home doubledigit sales growth part minds french people personalized skin care caring fulfills new needs new markets n northern china young children like wenjuans son zhang chenyuan spend lots time playing outside see chapped face know hes uncomfortable says one mothers followed lillian xu consumer innovation center emic squaremeter science manager asia pacific emerging markets johnson johnson facility opened shanghai johnson johnson group consumer companies emerging markets like brazil india china others represent colleagues part consumer closeness bonding program almost percent worlds population spending program integral part product design develop power categories serving growing significantly says ment emerging markets found moms apply gerson pinto vice president research development cream babys face morning go says asia pacific emerging markets johnson johnson group xu reapplication day evening regarded consumer companies mission emic develop new wasteful unnecessary affordable products addressing specific consumer needs findings considered development emerging markets september launch johnsons baby long protecting emic researchers product developers continue cream clinically proven replenish skin lipids lost chilly observe strive meet needs growing markets dry wind winter creams natural ingredients part consumer closeness experience says competitively priced gram package meet needs chinas excited johnson johnson people get know needs emerging market developed emerging market able develop products directly problem enjoying outdoors wenjuan son zhang chenyuan part consumer bonding program china allowed researchers see firsthand need longlasting cream keep childrensc heeks chapping johnsons baby long protecting cream launched september shaping johnson johnson served official health talent shortage potential bottleneck care sponsor beijing olympic games accelerating business growth china explains future paralympic games sponsorship helped wen jian xie managing director johnson johnson shape growth china creating deeper medical china ltd building reputation china emotional connection chinese people sponsorship led much better talent johnson johnson says owen rankin vice recruitment retention xie says people china president corporate equity johnson johnson expanded view johnson johnson fundamentally changed johnson johnson role providing best effective medical china last decades products customers china serving many sponsorship involved four years planning patients improving quality health care preparation execution conjunction olympic games johnson johnson games provided successful boost businesses helped better health wellbeing families around world especially china since establishing communities education information joint venture johnson johnson built supported olympic athletes medical staff investmentsincluding recent acquisition beijing training products education see dabao cosmetics co ltd see johnson johnson beijing science center built helped preserve chinese heritage accelerated train medical professionals region helped largerthanlife marionettes standing feet tall growth important emerging market chinese physicians medical personnel prepare told story ancient terracotta warrior brought beijing olympic games games remains functioning training facility life young chinese girl vibrant cultural unprecedented opportunity enhance reputation supporting growing health care infrastructure china performance presented johnson johnson china caring trusted health company helping johnson johnson olympic games pavilion millennium monument park beijing businesses grow faster building deeper located beijing olympic green donated olympic games introduced past present relationships government people china city beijing enduring reminder spirit visibly demonstrated strong past future making johnson johnson attractive place caring sharing creates healthier societies commitment people china work says rankin goals achieved around world johnson johnson annual reportour caring heals skin hes f years troy depriest centocor scientists discovered ustekinumab human monoclonal antibody years ago targets endured painful red lesions proteins cytokines thought set certain covered much body inflammatory disorders including psoriasis ustekinumab binds interleukin prevents characterize plaque interaction cell surface receptors essentially psoriasis like many others neutralizes bioactivity explains jacqueline benson phd living psoriasis troy assistant director immunology research centocor inc hope benefit ustekinumab demonstrated embarrassed physical signs patients psoriasis beginning therapeutic disease id go surfing id go use ustekinumab immunemediated diseases two large clinical studies evaluated efficacy far end beachi wanted isolate safety ustekinumab infrequent subcutaneous injection people stared patients receiving four injections year following two initial doses weeks twothirds clinical made feel like leper says trial patients receiving ustekinumab significant response itchy scales first appeared troy would weeks therapy studies continue longterm scratch dig scalp would bleed recalls extensions provide total five years efficacy time raised red spots took portions back safety data ustekinumab legs arms abdomen age troy diagnosed stelara ustekinumab approved regulatory chronic severe plaque psoriasis inflammatory disorder authorities canada european union countries painful physically emotionally plaque psoriasis treatment moderate severe plaque psoriasis stelara contagious makes selfconscious want currently review us food drug administration hide says troy strips away confidence marketing applications treatment moderate find relief troy says tried multiple therapies even severe plaque psoriasis filed local health authori moved home massachusetts california desert ties numerous regions around world hoping sun would help skin nothing worked says today troy active raising awareness every day would get look mirror see national psoriasis foundation psoriasis improved disease getting worse worse one point gave wanted get help others says youll troy learned clinical trial inves find foundation walk speaking burden tigational therapy centocor inc called ustekinumab psoriasisor may find beach everything decided enroll study ustekinumab new biologic focused psoriasis feel comfortable medicine johnson johnson worldwide marketing living life rights trade name stelara participation selfconfident plaque psoriasis contagious trial troy went significant percentage makes selfconscious want hide says body involved psoriasis significant improvement troy depriest since hes found relief investigational disease says dermatologist stacy smith president treatment centocor inc troy longer hiding therapeutics clinical research san diego far end beach johnson johnson annual reportjohnson johns annual repor corporate level revisions pharmaceuticals us tekinemabour caring generates green power c ork nice town friendly peoplethe drawback rain says ibrahim khadra staff engineer global pharmaceutical supply group llc worldwide engineering looks back recently completed threeyear assignment ireland course theres advantage rain keeps country green greengreen poweris brought khadra ireland project lead responsible building megawatt biomass boiler uses wood chips centocor biologics ireland manufacturing facility biocork boiler replaces half natural gas used facility reduces carbon dioxide co emissions percent wood chips fuel boiler byproducts branches logging sustainable forests near cork biomass first biotech completed september biomass boiler first project kind within johnson johnson biotech sector cilag ag pharmaceu tical manufacturing facility switzerland also uses biomass wood chips burn carbon dioxide released boiler first installation pharmaceutical company atmosphere ash produced burning process collected ireland never slam dunk says khadra nobody used fertilize new trees absorb co completing done biotech facility think biomass sustainable carbonneutral cycle think burning wood chips think dirty operation biocork manufactures monoclonal antibodies basis reducing emissions johnson johnson began setting biologic medicines ustekinumab see story environmental goals established goal khadra says making biomass boiler clean contained reduce co emissions facilities worldwide percent operation intriguing challenge given delicate require absolute terms improving energy efficiency ments producing monoclonal antibodies establishing onsite cogeneration renewableenergy projects came idea hook bins essentially converted using green power purchasing carbon offsets company trailers designed moving floors allow us handle target meet goal see map worldwide sustainability wood chips clean contained way says khadra projects www jnjcom wood chips fed auger boiler biocork facility built burned heat water resulting steam used heat strong commitment reduce new sites carbon footprint facility run manufacturing process approximately percent initial design looked johnson johnson annual reportcaring f environment youre outside ireland feel alive says ibrahim khadra staff engineer global pharmaceutical supply group llc worldwide engineering khadra got involved building biomass boiler centocor biologics ireland ltd motivated goal reduce co emissions johnson johnson facilities worldwide percent absolute terms says fact alone makes want everything come innovative ideas ways reduce carbon footprint number ways minimizing impact environ johnson johnson worldwide environment health safety ment including biomass boiler says jonathan sowerbutts category winner sustainability facility director engineering centocor biologics ireland ltd year award ispe interphex pharmaceutical financial particularly environmental benefits processing magazine outweighed adding cost complexity overall project khadra worked building centocor inc biologic facility malvern pa readily sees learning making impossible possible sowerbutts khadra past makes biocork current best practice emphasize project could happened without learned biomass boiler im hoping biomass significant organizational support received biocork boiler project allows impossible become possible since internal external awards including khadra says see todaythe biomass boiler running excellence award design construction startup clean process isyouve seen possible green po wer caring touches diabetes remotely adison diabetes needs give insulin eight times day active teenager could easily embarrassing debilitating new insulin pump madi gets insulin needs class roller rink friends hardly notice looks like im texting says people see anyone else madi uses onetouch ping glucose management franchise committed raising standard care world system first fullfeature insulin pump meterremote wide global epidemic affects nearly million launched first integrated product twoo f people growing alarming rate companies comprise diabetes care franchise animas end johnson johnson diabetes institute llc corporation maker insulin pumps johnson johnson launched first center united states acquired lifescan inc maker onetouch california facility provides product training education brand blood glucose meters thousands communitybased health professionals led animas lifescan companies focus patients like former acting us surgeon general kenneth p moritsugu md madi develop full spectrum solutions manage diabetes mph johnson johnson diabetes institute centers also patient center leads holistic approach operate china france japan plans patient care companies comprise diabetes care continue expanding globally johnson johnson annual report johnson johnson annual report corporate level revisions pm comprehensive care diabetes johnson johnson annual report corporate level revisions pm comprehensive care diabeteson go madi discreetly manages diabetes doesnt let get way active teenager reassure kids everything going ok people would never think oh diabetes people say wow shes active thats message want get live lifestyle also lifescan acquired children diabetes inc like wear dresses way take insulin wwwchildrenwithdiabetescom respected online ladylike composure madi says community offers sciencebased education friend school unzips pink purse pulls meterremote ships also sponsors family conferences spanishlanguage looks like cell phoneand checks blood glucose diabetes website diabetes juvenil wwwdiabetesjuvenilcom level madi makes calculations meterremote joined children diabetes cwd october instruct pump concealed clothes deliver insulin diabetes juvenil one biggest online communities even girls table notice less minute spanishspeaking families living type diabetes together madi back lesson really easy eighth grader says cwd diabetes juvenil help meet needs families also works active lifestyle madi often needs insulin affected diabetes around world roller hockey games sings dances shows longer access pump secured really easy diagnosed type diabetes age madi uniform costume days wears pink pump felt embarrassed pulling needles public welts belt loop matches outfits says smile multiple injections hurt danced played roller madi passionate helping kids diabetes hockey age switched animas insulin pump advocate american diabetes association ada delivered insulin small tube attached body madi organizes skating fundraisers local rink creates checking blood glucose level madi would make colorful journals sell captain ada walk team quick calculation determine insulin needs press madisons prayer one biggest child fundraisers buttons pump send appropriate amount raised madi also visits children newly insulin made life much easier says diagnosed diabetes share story deliver bags managing diabetes became easier still decorates fills gifts information onetouch ping glucose management system madi made promise im going help says doesnt touch pump day instead wireless dream finding cure im everything meterremote sends signal pump deliver insulin power help diabetes remotely johnson johnson annual report corporate level revisions pm comprehensive care diabetesour caring empowers living positively eight months pregnant kangela received heartbreaking news hivpositive like whole world come safely feed babies encourage end says kangela lives south africas women join mm support group eastern cape region didnt know moms share stories form friendships thinking baby going die going mentor mothers strength tell mom deal community transformational families south africa kangela alone fears sub says dr besser women longer feel like saharan africa million people outcasts society belong vibrant infected hiv representing twothirds community raising healthy babies worlds hiv population according living positive lives unaids figures infected women become pregnant risk passing virus children power partnering mm program leaders first came practice medicine say partnerships business government south africa programs groups allowed program resources hivpositive women says grow reach women every day obstetriciangynecologist mitch besser md johnson johnson helped establish two mm founder organization mothersmothers sites currently supports sites across mm people werent getting tested women east london port elizabeth cape town area didnt know feed babies without work mm johnson johnson passing virus terrified received award business excellence disclose hiv status family members hivaids addressing women girls overworked doctors nurses little time global business coalition hivaids provide support hiv patients tuberculosis malaria mm program decided train another kind health care among hivaids programs providermothers living hiv johnson johnson supports across countries says dr besser cape town established partnership johnson johnson first mothersmothers program allowed us reach enormous numbers hivpositive mothers began serving mentors women says dr besser want take mm sharing experiences knowledge program everywhere needed began moms simple idea changed way thousands women feel cope live mothers helping mothers mm program grown program sites mantra infected reaching women month babies dying mothers mm moms trained mentors including mantra says kangela time looks kangela dr besser says nearly yearold son smiles son healthy hivpositive women participate cute playful proof hope program hivnegative babies look forward day raise women come us crying children hivfree generation scared tell story finding hope kangela hivpositive hivpositive child hivnegative mother mentor mothersmothers says kangela tell going make program south africa program raise healthy baby yearold son born without contracting mentor mothers talk women disease mother mm among condom use importance early infant hivaids programs testing proper diet antiretroviral treatments johnson johnson supports across countries johnson johnson annual report corporate level revisions mothers mothers johnson johnson annual report corporate level revisions mothers mothersjohnson johnson annual report corporate level revisions mothers mothers year review consumer health care overthecounter science drives zyrtec development launched skin care january mcneil consumer science catalyst healthcare division mcneilppc inc behind many growth launched zyrtec cetirizine hcl sale strategies includes without prescription united states organic growth iconic largest rxtootc switch brands new ventures companys history otc rights even emerging markets market zyrtec scientific launch prescription allergy technical challenge medicine us gained develop grow part pfizer consumer products effective healthcare acquisition appealing provide early launch efforts focused ensuring value consumers large percentage zyrtec across cultures prescription users followed brand socioeconomic groups rx otc side also worked worldwide demand grow market capture share products using natural allergy sufferers using rx otc ingredients continues drive growth batteryoperated handheld applicator medications zyrtec would aveeno brand uses helps get rid stubborn blackheads appropriate zyrtecd cetirizine hcl sciencebased approach develop active prevent new ones forming brand mgpseudoephedrine hcl mg naturals superior efficacy long continued expand internationally launching combines zyrtec decongestant known natural oatmeal products successfully india campaign launched time aveeno expanded lineup natural culturally relevant television advertising working pharmaceutical ingredients include soy feverfew pfe business important component natural shiitake complex among others johnsons grows globally launch success allowing mcneil aveeno continued grow presence countries johnsons consumer healthcare work health introducing aveeno positively baby continued gain new users care plans pharmacy benefit managers ageless lifting firming facial grow business international markets national retailers employers skincare line natural shiitake complex growth driven focus core zyrtec launch educate inform natural wheat protein line business including original pink switch thanks efforts includes daily exfoliating facial cleanser johnsons baby lotion millions zyrtec prescription users rejuvenating serum eye cream daily clinically superior formulation received switch moisturizer spf night cream moisturizes hours information designed work skins johnsons body care experienced coupon chemistry deliver antiaging benefits strong growth japan thanks successful health clinical studies percent women showed extension adult moisturizers plan millions improvement four weeks cleansers johnsons brand zyrtec skin care news clean clear japanese body lotion market allergy skin care brand young women body cleansers prescription users built leadership position johnsons also providing received similar continued success advantage innovative solutions consumers communication acne control kit also launched emerging markets notably driving advantage blackhead eraser switch bar soap johnsons liquid employer exfoliating cleanser waterresistant cleansers milder less irritating johnson johnson annual reporta sciencebased approach growth connecting clinically proven efficacy consumer insights many brands recommended health care professionals oral care reaches new markets expanding presence china johnson johnson healthcare products division mcneilppc inc continues driving force oral care category marketing worlds mouthwash listerine continue see strong growth brands like listerine thrived generations thanks innovative products science based claims based deep consumer insights geographic expansion helping drive growth august launched listerine total care united kingdom helped deliver strong results listerine brand europe total care advanced complete listerine mouthwash first combine range benefits reduces plaque kills bacteria fights bad breath keeps gums healthy strengthens teeth fluoride keeps teeth naturally white also reinforced reach lines emphasizing angled neck reach toothbrush introduction reach ultraclean brush removes percent plaque hardtoreach places time ultraclean floss revolutionary micro grooves technology gives consumers theyve looking fora floss slides easily removes plaque effectively years johnson johnson consumer promoted health wellbeing china skin care segment baby care built presence sales acquisition beijing dabao cosmetics company ltd sales major franchise billions dollars first personal care acquisition sales billion china brings countrys growth rate womens moisturizer brand wellknown health respected among chinese consumers transaction extension commitment china continued development consumer health care sector since establishing first joint venture china johnson johnson family companies wound continuously demonstrated care commitment improving health wellbeing chinese families china otc pharmaceuticals important market nutritionals dabao skin care line includes oral care various products wellknown chinese households including sod milk beauty day includes rounding cream sod protein milk year review year review pharmaceuticals rd productivity key future growth sustaining rd productivity reducing time cost maintaining quality fundamental imperatives pharma ceutical business recently pharmaceutical industry facing growing generic competition demanding regulatory environment seen oncestrong pipelines soften time however sustained research productivity track complete filings seven new products beginning end well meet goal set back demonstrating achieved dedicated employees work together moving new compounds concept reality organic growth well strategic inlicensing partnerships contributed reaching regulatory milestones success driven research development use new biologic members ustekinumab compound development team discovered human monoclonal antibody years ago approved expertise biopharmaceuticals canada eu countries review us fda small molecules focus effectively discovery development new molecular biologics license application bla centrally acting oral analgesic entities pursuing innovative platforms submitted fda requesting comprehensive dual mechanism action technologies drug delivery approval golimumab cnto combining muopioid receptor agonism highlights significant nextgeneration human antitnfalpha norepinephrine reuptake inhibition regulatory milestones monoclonal antibody monthly significantly relieve moderate subcutaneous treatment adults severe acute pain low incidence immunology active forms rheumatoid arthritis gastrointestinal side effects nucynta stelara ustekinumab new biologic psoriatic arthritis ankylosing codeveloped grnenthal medicine johnson johnson spondylitis developed johnson johnson pharmaceutical worldwide marketing rights subcutaneous injection intravenous research development llc jjprd approved regulatory authorities infusion therapy potential claims canada european union uses studied include impact cardiovascular countries treatment moderate structural damage related rheumatoid new drug application nda filed severe plaque psoriasis stelara arthritis ulcerative colitis fda rivaroxaban currently review us food investigational oral oncedaily anticoagulant drug administration fda marketing pain management prevention deep vein thrombosis applications treatment moderate nucynta tapentadol immediate dvt pulmonary embolism pe severe plaque psoriasis filed release tablets granted fda approval patients undergoing hip knee replacement local health authorities numerous relief moderate severe acute surgery initially developed prevention regions around world pain adults age older nucynta dvt pe hip knee replacements johnson johnson annual reportinnovative platforms technologies driving growth promising early latestage pipeline nine products revenue billion larger opportunities exist rivaroxaban use combination antidepressants coccus aureus mrsa janssencilag possible additional indications andor mood stabilizers market drug licensed venous thromboembolism treatment stroke nda submitted fda codeveloped basilea pharmaceutica prevention atrial fibrillation prevention carisbamate investigational compound ltd zevtera switzerland dvt pe patients hospitalized adjunctive treatment partialonset medical illnesses acute coronary seizures patients age older continued growth syndrome jjprd cdeveloping jjprd sk holdings co ltd entered addition several currently marketed rivaroxaban bayer healthcare ag license agreement develop wellperforming products received regula holds marketing rights countries outside commercialize carisbamate jjprd tory approval new indications received us drug approved fda receiving global marketing rights approvals additional markets orthomcneil division orthomcneil european commission approved janssen pharmaceuticals inc market infectious disease oncedaily dosing mg prezista us zeftera ceftobiprole darunavir lowdose ritonavir part approved switzerland canada combination therapy treatmentnave central nervous system ukraine treatment complicated adults never taken hiv two supplemental new drug applications skin soft tissue infections medication approval broadens sndas submitted fda review us europe australia previous indication darunavir treatment requesting approval use invega several countries ability experienced hiv patients means paliperidone tablets treatment address broad range serious bacteria prezista used full spectrum schizoaffective disorder monotherapy including methicillinresistant staphylo adult hivaids patients eu member states us prezista pharmaceutical received full approval twicedaily use segment sales aciphexpariet treatmentexperienced adult patients sales major product expanded indication oncedaily dosing billions dollars part hiv combination therapy patients duragesic sales billion never taken hiv medicines growth rate intelence etravirine levaquin fda approved early received floxin marketing authorization canada eu hiv combination therapy concerta snda submitted combination doxil doxorubicin hcl liposome injection taxotere risperdal docetaxel treatment women consta topamax advanced breast cancer received prior anthracycline treatment nda submitted use trabectedin combination doxil risperdal treatment women relapsed ovarian cancer trabectedin procriteprex remicade developed license pharmamar doxil marketed ortho biotech includes rounding products lp united states year review year review medical devices diagnostics ethicon endosurgery ethicon transforms patient care strengthens foundation late johnson johnson acquired omrix biopharmaceuticals inc fully integrated biopharmaceutical company develops markets biosurgical immunotherapy products omrix expected operate standalone entity reporting ethicon inc acquisition provides ethicon opportunity strengthen presence active biologic based hemostats convergent products various surgical applications ethicon currently exclusive us european union distribution rights evithrom thrombin topical human evicel fibrin sealant human ethicon endosurgery inc continued interactive oneofakind support system two active biologicbased hemostats drive business growth number guides patients path lifestyle manufactured omrix ethicon omrix strategic achievements new existing changes help sustain weight loss also partnering fibrin pad product markets march company submitted use realize mysuccess program candidate currently phase ii clinical premarket approval application us starts surgery continues well trials adjunct control mild food drug administration fda october ethicon endosurgery moderate soft tissue bleeding sedasys system first computer advanced rich history investing rd early johnson johnson assisted personalized sedation caps completing acquisition surgrx inc completed acquisition mentor system intended use physician privately held developer advanced corporation leading supplier medical nurse teams administering minimal bipolar vesselsealing technology used products global aesthetic market moderate propofol sedation patients enseal family devices acquisition mentor expected operate stand undergoing screening diagnostic brings together two leading complementary alone business unit reporting ethicon procedures colorectal cancer energy technologies rapidly evolving acquisition provide ethicon disorders upper gastrointestinal tract global energy segment combined opportunity strengthen presence building commitment longterm portfolio enseal products aesthetic reconstructive medicine patient outcomes ethicon endosurgery ethicon endosurgery harmonic line expanding capacity provide physicians received fda approval realize ultrasonic medical devices offers greater products restore patients adjustable gastric bandc newest functionality flexibility diverse appearance selfesteem quality life addition realize personalized surgical procedure requirements ethicon mentor two companies banding solution weight reduction committed bringing evidence people suffering morbid obesity based medicine highest standards realize bandc offers streamlined quality aesthetic reconstructive curved design expanded adjustment medical device category companies range accommodate larger patients share commitment science health realize band patients go relockable closing mechanism intra wellness mentor become cornerstone wwwrealizebandcom learn real operative repositioning addition people receiving support achieve longterm broader johnson johnson leadership realize mysuccess program extends weight loss realize personalized strategy aesthetic medicine serving continuum care webbased banding solution consumers medical professionals johnson johnson annual reportlargestmedicaldevicecompanyintheworld noornointhemajorityofmarketsinwhichwecompete wellpoisedforgrowth new era vision care franchise diagnostics continues grow theorthoclinicaldiagnosticsincocd oftheartmanufacturingplantinpencoed fullyintegratedglobalbusinesscomprises walesandanacquisitionsecuringapointof laboratorytestsandinstrumentation carechannelthatwillallowthecompanyto foruseintransfusionmedicineandclinical bringdiagnosticsdirectlytothephysician laboratoriesocdisdrivinggrowthinits diagnosticsplayamajorroleinhealth corebusinesseswithnewproducts careoutcomesmorethanpercent andlaunchinghighimpactmedicaltestsin ofhealthcaredecisionsaremadeusing molecularandcellulardiagnosticsthat diagnostictestresultsmatchingdiagnostics willcreateanentirelynewtypeofvaluefor withtherapiesallowsforamoretargeted johnsonjohnsonvisioncareinc themedicalsystem approachprovidinginformationthatphysicians continuestomaintainitsleadership inthecompanybroughttomarket canusetoimprovepatientoutcomes positionlaunchingnumerousinnovative twonewlaboratorysystemsthevitros diagnosticscanhelpjohnsonjohnson eyecareproductsdesignedtoimprovethe integratedsystemandthevitros achieveorganicconvergenceleveragingits livesofpatientseverywhere immunodiagnosticsystemthese broadbasedpositioninhealthcare acuvueremainstheworldsmost nextgenerationinstrumentsaredesigned todrivenewapproachesinpatientcareocd widelyprescribedcontactlensbrandin torunmorethanclinicalchemistryand iscommittedtobringingproductstomarket thebrandgrewwiththeadditionoftwo immunoassaytests thatcanidentifyillnessesinadvanceof newproductsacuvueoasysbrand ocdhasastrongpipelinethatissupported diseasepotentiallyavoidingprogressionto contactlensesforastigmatismand byrecentinvestmentsincludinganewstate moreseriousdisorders introducedintheunitedkingdomday acuvuetrueyetheworldsfirstdaily medical disposablesiliconehydrogelcontactlens devices ende ot h suic ro gn ery buildingonitspartnershipwitheyecare diagnostics depuy practitionersthevisioncareinstitutellc segment nowhasmorethansisterinstitutesinsuch diversecitiesasbangkokshanghaitokyo sales pragueanddubailaunchedinasa salesby sourceofcontinuouslearningand majorfranchise diabetes inbillionsofdollars care informationthevisioncareinstitute sales llcanditssisterunitshavetrainedmore billion thaneyepractitionersworldwide growthrate acuvuecontinuestobeinnovativein otherwayssuchasusingdigitalmediawith toolslikeacuminderacomplimentary orthoclinical onlineservicewwwacumindercomthat diagnostics sendsanautomaticreminderviaemail textmessageorcomputerpromptto ethicon changeorordernewcontactlensesthe expandedfunctionalityofacuminder facebookwwwacumindercomfacebook visioncare alsoallowsuserstosendoutremindersfor cordis justaboutanythingsuchastakingdaily medicationsdoctorsvisitsworkdeadlines includesrounding socialeventsandmore year review depuy helps patients lifescan reaches never stop moving patients within orthopaedic market depuy surgical precision flexibility franchise leading fullline player sigma ps femur optimizes function products services span entire fit highdemand patients entering orthopaedic care continuum early growing agingspine market depuy intervention joint replacement spine introduced confidence trauma spinal fusion neurosurgical spinal cement system vertebral care companiesdepuy orthopaedics compression fractures inc depuy spine inc depuy mitek inc enhance patient education codman shurtleff incare increasingly orthopaedic procedures depuy developed focused meeting patient needs earlier integrated initiative us themed care continuum never stop moving campaign lifescan inc leading maker franchise introduced featured mike krzyzewski coach k blood glucose monitoring products products significant new joint depuy hip patient coach us demonstrated commitment people replacement products include trilock olympic team mens basketball duke diabetes continuous innovation bone preservation stem proprietary university basketball goal motivate lifescan introduced onetouch gription technology stability osteoarthritis sufferers learn ultralink blood glucose meter enhancements sigma knee system treatment options seek care new exclusive meter wireless include sigma high performance orthopaedic surgeon patients visit communications use medtronic instruments enhance procedure efficiency wwwdepuyusacom learn insulin pumps united states uses medtroniccertified wireless technology cordis transforms cardiovascular care transmit glucose readings directly minimed paradigm insulin pumps making bolus dosing accurate easier manual entry blood glucose cardiologists worldwide chosen cordis corporations flagship product cypher readings lifescan also introduced two new sirolimuseluting coronary stent treat million patients coronary colors onetouch ultramini artery disease clinical trials way around world support two new blood glucose meter purple twilight drugeluting stents cordis cypher elite sirolimuseluting coronary stent blue comet offered six colors nevo sirolimuseluting coronary stent nevo stent utilizes new become selling blood reservoir res technology avoids need surface coating rather stent glucose meter us hundreds small holes reservoirs stent struts loaded bioresorbable drug europe approximately polymer matrix drug delivered biodegradable coating dissolves million people diabetes lifescan leaving behind baremetal stent approach intended provide launched onetouch vita blood degree restenosis prevention conventional drugeluting stent faster glucose meter using mealmemory complete vessel healing stent implantation technology calculate blood glucose also cordis announced placement one millionth smart nitinol averages based day periods selfexpandable stent system used treat range peripheral vascular diseases new meter may particular benefit early cordis biosense webster unit received us fda approval people type diabetes find navistar thermocool catheter treatment atrial fibrillation abnormal heart disease complex difficult manage rhythm affects million people worldwide cardiac ablation energy delivered users also attach meal flag catheter areas heart muscle causing abnormal heart rhythm test result help link energy disconnects pathway abnormal rhythm first ablation effects theyve eaten blood catheter approved us treatment atrial fibrillation glucose level johnson johnson annual report year review wellness prevention wellness prevention platform keeps employees healthy engaged judy herlich tried many diets years weight always crept back herlich received email companys health benefits group inviting employees try healthmedia webbased program helps people improve behaviors areas weight stress management sleep quality smoking cessation medication adherence herlich lost pounds healthmedia recommended online plan tailored four years later kept weight definitely energy rarely call sick say herlich associate scientist johnson johnson pharmaceutical research development llc jjprd raritan nj johnson johnson established wellness prevention business platform deliver new growth company portfolio products services focused preventing chronic disease keeping people well restoring faculties lost aging global health care systems including governments employers individuals staying healthy judy herlich associate scientist jjprd uses many companys wellness programs stay healthy johnson johnson health wellness program focuses seeking new solutions spiraling health care keeping employees healthy containing health care costs increasing productivity costs wellness prevention platform recognizes comprehensive solution must productivity grounded sciences money improve productivity begin long onset illness performance psychology exercise physiology herlich says feels energetic investing wellness prevention nutrition teaches employees since began healthmedia avoid costly health care expenses later manage energy perform weight management program started also concluded two strategic best human performance exercising daily companys fitness acquisitions initial steps building institute cofounded center likes moderate exercise wellness prevention business october bestselling author dr jim loehr dr jack eating plans dont eliminate food acquired healthmedia inc offers groppel work past years groups rule says online health coaching users like herlich helped athletes military elite long stick plan percent proven outcomes increased corporations optimize performance time youll succeed time time productivity decreased medical usage initially johnson johnson updates personalized plan december acquired lge performance wellness prevention platform focused healthmedia programs grounded systems inc known human employers health care expenses science appealing participants performance institute among rapidly growing costs personalized easy develops sciencebased training programs employers efforts keep understand make sense real improve employee engagement employees well engaged save commonsense approach herlich says year review year review caring world caring family legacy philanthropy communities continues olympics years johnson johnson caring everyday people athletes johnson johnson long history promoted health wellbeing caring hearts contest giving dating back years local affiliates china continued hearts gold program legacy philanthropy guided carry torch proud sponsor years johnson johnson credo responsibility official partner beijing olympic partnered china qin shi huang communities live work paralympic games worldwide partner terracotta army museum use technology world community well international olympic committee establish center excellence work hundreds partners worldwide official health care products partner historic relic preservation xian helping strive make lifechanging longterm national olympic committees preserve lifesize terracotta warriors differences human health countries horses years india nepal pakistan olympics johnson johnson old beijing games company partnership unicef helps save helped better health wellbeing honored partnership providing newborns lives support training families communities education visitors johnson johnson olympic community health workers underserved information programs games pavilion rare opportunity view areas provide homebased newborn care johnson johnson family health initiative five qin shi huang terracotta warriors interventionsbreastfeeding support comprehensive campaign featuring number among th centurys significant treatment sepsis hypothermiato national health education programs archaeological finds also pavilion reduce infant mortality help families china enjoy happier largerthanlife marionettes told story europe partner insead healthier lives company supported ancient terracotta warrior brought european health leadership program olympic athletes medical staff life young girl marionettes providing health care industry managers training products education preserved xian museum leadership training help advance celebrated inspired extraordinary acts companys work china see roles rapidly changing industry north america partnership wharton school provided senior nurse executives business management skills past years mexico underserved school children parents teachers benefited awareness campaigns connection diabetes obesity also known diabesity partnership project hope promote childrens eating exercise habits educate families teachers conveying positive nutrition messages children following earthquake sichuan china provided product monetary donations acute relief longterm psychological health rehabilitation efforts thousands families chairman ceo coled us governments publicprivate partnership mission china explore longterm rebuilding efforts johnson johnson annual reporta paperless sustainability measures notification process doctors company longstanding sustainability important part business efforts ability protect commitment patient product safety environment respect employees responsible world community data johnson johnson pleased partner summary table provides sampling sustainability programs johnson johnson health care notification network operating companies learn programs visit wwwjnjcom hcnn rolled october environmental indicators unit using electronic communication methods hcnn dramatically carbon dioxide net emissions thousand metric tons improves process notifying us voluntary co offsets incl recs thousand metric tons physicians timesensitive important water use million patient safety information provides timely effective efficient delivery nonhazardous waste million kg information nations physicians hazardous waste million kg manufacturers recognizing importance groundbreaking communication system employee health indicators unit free licensed us physicians tobacco use profiled employees staff hcnn used solely high blood pressure profiled employees fdamandated patient safety alerts fulfilling recently updated fda guidance high cholesterol mgdl profiled employees electronic delivery alerts inactivity profiled employees physicians health care providers minday daysweek register receive electronic alerts www hcnnnet participating medical employee safety indicators unit societies hcnn partners serious injuryillness rate incidents per employees hcnn green initiative reduces paper usage need mail delivery lost workday case rate incidents per employees partnering russia fleet car accidents accidents per million miles driven patients ergonomic injuries lost workday cases unique partnership johnson johnson accesswellness medical russia along janssencilag working russian ministry expands language options health achieve professionaleducation goal creating russian center professional education kazan accesswellness program offers single entry point one broadest center capacity train selections patient assistance programs available spanish located physicians every year two training wwwaccesswellnesscom spanishlanguage service provides access free centers russia planned discounted prescription medications uninsured underinsured people qualify partnership help improve health care accesswellness divided sections developed address specific needs access patients providing better patients caregivers health care professionals hospital administrators advocate organiza training physicians ultimately tions exclusive accesswellness online eligibility tool offers quick easy way access improved medical technologies find assistance programs available qualifies year review board directors first row left right william c weldon chairman board directors chief executive officer mary sue coleman phd president university michigan second row left right james g cullen retired president chief operating officer bell atlantic corporation michael e johns md chancellor emory university third row left right arnold g langbo retired chairman chief executive officer kellogg company susan l lindquist phd member former director whitehead institute biomedical research professor biology massachusetts institute technology fourth row left right leo f mullin retired chairman chief executive officer delta air lines inc william perez retired president chief executive officer wm wrigley jr company fifth row left right charles prince chairman sconset group vice chairman chairman board advisors stonebridge international llc retired chairman chief executive officer citigroup inc david satcher md phd director center excellence health disparities director satcher health leadership institute poussaintsatchercosby chair mental health morehouse school medicine former us surgeon general johnson johnson annual reportcommittees nominating corporate governance nominating corporate governance committee board comprised entirely independent directors responsible overseeing corporate governance matters reviewing possible candidates board membership recommending nominees election committee also responsible overseeing process performance evaluations board committees additionally committee reviews companys management succession plans executive resources charles prince chairman audit james g cullen audit committee comprised entirely independent arnold g langbo directors helps board oversee companys accounting reporting practices recommends independent public accountants appointment board reviews per public policy formance monitors adequacy internal accounting public policy advisory committee reviews practices procedures controls reviews significant companys policies programs practices public health changes accounting policies issues regarding environment health safety employees committee also reviews companys james g cullen chairman governmental affairs policies public policy issues mary sue coleman phd facing company committee advises makes leo f mullin recommendations board issues appropriate public policy advisory committee comprised independent directors companys general counsel compensation benefits vice presidents corporate affairs government affairs compensation benefits committee comprised entirely policy worldwide operations independent directors establishes companys executive compensation philosophy principles approves leo f mullin chairman annual compensation longterm incentives russell c deyo companys directors executive officers committee clifford e holland also reviews philosophy policies nonboard susan l lindquist phd management compensation committee determines william perez management compensation establishes perquisites brian perkins compensation policies nonexecutive employees david satcher md phd additionally committee oversees management ajit shetty phd various retirement pension longterm incentive savings health welfare plans cover companys employees science technology arnold g langbo chairman science technology advisory committee comprised michael e johns md independent directors companys vice president william perez science technology advises board scientific charles prince matters including major internal projects interaction academic outside research organizations acquisition technologies products finance finance committee exercises management authority david satcher md phd chairman board intervals board meetings mary sue coleman phd finance committee comprised chairman michael e johns md board presiding director susan l lindquist phd garry neil md william c weldon chairman james g cullen board directors committees board corporate officers william c weldon alex gorsky executive committee chairman board directors worldwide chairman johnson johnson principal chief executive officer surgical care group management group responsible chairman executive committee executive committee operations allocation resources company dominic j caruso raymond c jordan committee oversees vice president finance vice president public affairs coordinates activities chief financial officer corporate communication consumer pharmaceuticals executive committee medical devices sherilyn mccoy diagnostics business segments donald casey jr worldwide chairman subsidiary within worldwide chairman pharmaceuticals group business segments comprehensive care group executive committee exceptions managed citizens executive committee country located john papa stephen j cosgrove treasurer corporate controller brian perkins laverne h council vice president corporate affairs vice president chief information officer steven rosenberg secretary russell c deyo associate general counsel vice president general counsel executive committee nicholas j valeriani vice president office kaye fostercheek strategy growth vice president human resources executive committee executive committee colleen goggins worldwide chairman consumer group executive committee company group chairmen joaquin duato david norton michael e sneed seth h z fischer michel paul pericles p stamatiades guy j lebeau md kristine peterson paul stoffels md karen licitra gary j pruden jesse j wu michael f mahoney marc e robinson patrick mutchler jose v sartarelli phd johnson johnson annual reportcorporate governance managements responsibility johnson johnson guided values set forth credo pricewaterhousecoopers llp independent registered public created general robert wood johnson principles accounting firm engaged perform integrated audit guided us years continue set tone consolidated financial statements internal control financial integrity entire company levels employees reporting report independent registered public accounting johnson johnson committed tothe ethical principles embod firm onpage ied credo principles woven audit committee board directors composed fabric company solely independent directors financial knowledge values articulated credo extend accounting experience provide appropriate oversight review internal financial responsibilities johnson johnson shareholders control matters key accounting financial reporting issues investors management johnson johnson audit committee regular basis addition inde responsible integrity objectivity accompanying pendent auditors general counsel vice president financial statements related information also responsi internal audit regularly meet private sessions audit ble ensuring financial data reported accurately committee discuss results work including observa manner facilitates understanding thisdata tions adequacy internal financial controls quality evidence commitment responsibility offinancial reporting confirmation properly maintain welldesigned system internal accounting controls discharging responsibilities relevant matters encourage strong effective corporate governance executive committee continuously involved board directors continuously review business results review financial results well developing understanding strategic choices focus financial stewardship strategies key initiatives longterm growth intent corporate staff professionally trained internal auditors ensure maintain objectivity business assessments travel worldwide monitor system internal accounting constructively challengethe approach tobusiness opportunities controls designed provide reasonable assurance assets issues monitor business results related controls safeguardedand transactions events recorded properly consolidated financial statements financial data internal controls include selfassessments internal reviews follow prepared conformity accounting principles operating companies generally accepted united states america include companycontinued toinvest significant amounts based upon best judgments commit timeand resources order ensure compliance section ted present discuss results operations clear sarbanesoxleyact based work per transparent manner order provide timely comprehensive formed concluded internal control financial andunderstandable information shareholders reporting effective december refer managements report internal control financial reporting werequire management teams operating companies tocertify compliance policy business conduct william c weldon dominic jcaruso wehaveasystematic program designed ensure compliance chairman boardof vicepresident finance policies view policy onbusiness conduct please visit directors chief chief financial officer website wwwinvestorjnjcomgovernanceconductcfm executive officer table contents managementsdiscussion analysis audited consolidated financial statements organization business segments consolidated balance sheets results operations consolidated statements earnings analysis sales bybusinesssegments consolidated statements equity analysis consolidated earnings provision consolidated statements cash flows taxes income notes toconsolidated financial statements liquidityand capital resources reportofindependent registered public accounting firm information managements report internal control cautionary factors may affect future results financialreporting summary operations statistical data shareholder return performance graphs reconciliation nongaap financial measures johnson johnson annual report managements discussion analysis results operations financial condition organization business segments managements objectives aprimary objective company achieve superior levels description company business segments capital efficient profitable growth accomplish com johnson johnson subsidiaries company panys management operates business consistent certain approximately employees worldwide engaged strategic principles proven successful time research development manufacture sale broad range end company participates growth areas human health care products health care field company conducts business committed attaining leadership positions growth virtually countries world primary focus products areas development innovative products services related human health wellbeing new products introduced within past five years accounted company organized three business segments approximately sales billion consumer pharmaceutical medical devices diagnostics sales invested research development consistent consumer segment includes broad range products used investment reflects managements commitment baby care skin care oralcare wound care womens health importance ongoing development new differentiated care fields well nutritional overthecounter pharmaceuti products services sustain longterm growth cal products products marketed general public operating companies located andsold distributors directly independent chain countries company views principle decentralized man retail outlets throughout world pharmaceutical segment agement asset fundamental success broadly includes products following therapeutic areas antiinfective based business also fosters entrepreneurial spirit combining antipsychotic cardiovascular contraceptive dermatology gas extensive resources large organization ability trointestinal hematology immunology neurology oncology pain react quickly local market changes challenges management urology virology products distributed company committed developing global business lead directly toretailers wholesalers health care professionals ers drive growth objectives businesses managed prescription use medical devices diagnostics segment longterm order sustain leadership positions achieve growth includes broad range ofproducts used principally profes provides enduring source value shareholders sional fields byphysicians nurses therapists hospitals diagnostic unifying management team companys dedicated laboratories clinics products include cordis circulatory employees achieving objectives credo credo disease management products depuys orthopaedic joint recon provides common set values serves constant reminder struction spinal care sports medicine products ethicons companys responsibilities customers employees com surgical care womens health products ethicon endosurgerys munities shareholders companybelieves basic minimally invasive surgical products lifescans blood glucose principles along itsoverall mission improving quality monitoring insulin delivery products orthoclinical diagnos oflife people everywhere enable johnson johnson tics professional diagnostic products andvistakons disposable continue tobeamong leadersin health careindustry contact lenses companysstructureis based upon principle results operations decentralized management executive committee johnsonjohnson principal management group responsible analysis consolidated sales operations allocation resources company worldwide sales increased billion compared committee oversees coordinates activities increases sales consumer pharmaceutical medical devices diagnostics increases consisted following business segments product lines company competes compa sales increase due volume nies local global located throughout world competi tion exists product lines without regard thenumber andsize price competing companies involved competition inresearch currency involving development improvement ofnew existing total products processes particularly significant development new innovative products important companys suc sales us companies billion billion cess areas business also includes protecting billion represents decrease companys portfolio intellectual property competitive envi increases respec ronment requires substantial investments continuing research tively sales international companies billion sales forces inaddition development maintenance billion billion represents customer demand companys consumer products involves increase significant expenditures advertising andpromotion johnson johnson annual reportusand salesby internationalsales segment foryears inbillionsofdollars inbillionsofdollars consumer us pharmaceutical international medicaldevices anddiagnostics fiveyear compound annual growth rates worldwide analysis sales business segments usand international sales respectively consumer segment tenyear compound annual growth rates worldwide us consumer segment sales billion increase international sales respectively change due operational growth remaining due positive currency fluctua tions us consumer segment sales billion increase salesby international sales billion increase geographic result operations due currency region fluctuations inbillionsofdollars overthecounter otc pharmaceuticals nutritionals us franchise sales billion increase e wu ero sp tee rnhemisphere primary contributor growth successful launch excludingus overthecounter zyrtec allergy product line us asiapacificafrica companyannounced voluntary labeling change childrens cough cold medicines regarding usage children age years encourage safe effective use prod ucts actions haveasignificant impact sales theotc pharmaceuticals nutritionals franchise skin carefranchise sales grewby billion international geographic regions experienced sales growth sales growth primarily due aveeno clean consisting europe western clear neutrogena johnsons adult product lines hemisphereexcluding us asiapacific well new products related acquisition beijing dabao africa regions sales increases include impact currency cosmetics co ltd baby care franchise sales grew fluctuations us dollar foreign currencies billion growth primarily international mar positiveimpacts europe western kets across product lines womens health franchise sales hemisphere excluding us asiapacific grewby billion primarily due successful africaregion launch new products oral care franchise sales grew company cus billion sales growth driven performance tomer represented total consolidated revenues listerine mouthwash product line consumer segment sales billion increase change due operational growth remaining due positive currency fluctuations us consumer segment sales billion increase international sales billion increase result operations due currency fluctuations acquisition pfizer incs consumer healthcare business net related divestitures increased total sales growth operational growth total consumer segment major consumer franchise sales change dollars millions vs vs otcpharmaceuticals nutritionals skin care baby care womenshealth oral care wound careother total managements discussion analysis results operations financial condition pharmaceutical segment oral us expired june loss market exclusivity pharmaceutical segment sales billion risperdal oral patent resulted significant reduc decrease operational decline tion sales us us sales risperdal oral increase due positive impact currency fluctuations billion first half fiscal year us sales us pharmaceutical segment sales billion decrease risperdal oral billion billion second half international pharmaceutical segment sales billion risperdal consta risperidone longacting injectable increase included operational growth treatment schizophrenia achieved sales billion related positive impact currency fluctuations representing increase compared remicade infliximab biologic approved treat prioryear growth due positive shift per day ment crohns disease ankylosing spondylitis psoriasis psoriatic therapies longeracting risperdal consta arthritis ulcerative colitis use treatment rheumatoid concerta methylphenidate hcl product treat arthritis achieved sales billion growth ment attention deficit hyperactivity disorder adhd achieved prior year growth driven increased demand due sales billion representing increase introduction new clinical data overall market growth sales results favorably impacted approximately remicade competing market experiencing million related change estimate accrued sales reserves increased competition due new entrants expansion anadditional contributor sales growth market growth indications existing competitors although original concerta patent expired topamax topiramate approved fdahas approved generic version substitutable adjunctive monotherapy use epilepsy well pro forconcerta two parties filed abbreviated new drug phylactic treatment migraines achieved sales billion applications andas generic versions concerta increase prior year growth primarily pending may approved time due increases migraine category partially offset generic levaquin levofloxacinfloxin ofloxacin competition certain markets outside us patent aciphexpariet rabeprazole sodium experienced sales topamax topiramate us expired september declines respectively versus prior year due injuly us food drug administration fda granted competition category duragesicfentanyl transdermal pediatric exclusivity topamax extends market fentanyl transdermal system sales declined versus prior exclusivity us march us sales year due generic competition topamax billion expiration product patent pharmaceutical sales werebillion repre orloss market exclusivity likely result significant senting growth prior year contributors reduction sales increase sales velcade bortezomib product procrit epoetin alfa eprex epoetin alfa com treatment multiple myeloma prezistadarunavir bined sales billion decline compared treatment hivaids patients invega paliperidone prior year decline primarily due declining markets oncedaily atypical antipsychotic forerythropoiesis stimulating agents esasin us fda company received regulatory approval issued order requiring labeling supplement making specific us canada european union intelencetmetravirine revisions label esas including procrit label hiv combination therapy stelaratmustekinumab procrit updated july based reviewof emerg approved canada european union treatment ing safety data use esas patients cancer outside moderatetosevere plaque psoriasis currently review us new competition emerging safety data issues fda addition nucyntatmtapentadol immediate contributed lower sales results eprex discussions release tablets relief moderate severe acute pain european regulators regarding changes label esas includ adults years age older approved us ing eprex nearing finalization company also received approvals expanding indica risperdal risperidone medication treats symp tions several key products including concerta treat toms schizophrenia bipolar mania irritability associated adhd adults ages us velcade combina autistic behavior indicated patients experienced sales decline tion melphalan prednisone treatment patients billion market exclusivity risperdal previously untreated multiple myeloma european union major pharmaceutical product revenues change dollars millions vs vs remicade infliximab topamax topiramate procriteprex epoetin alfa risperdal risperidone levaquinfloxin levofloxacinofloxacin risperdalconsta risperidone concerta methylphenidate hcl aciphexpariet rabeprazole sodium duragesicfentanyl transdermal fentanyl transdermal system total prior year amounts reclassified conform current presentation johnson johnson annual reportandprezista oncedaily dosing part hiv combination technology additional contributors growth therapy treatmentnave adults traditional approval realize gastric band us endoscopy products outside twicedaily dose foruse treatmentexperienced adult patients us us outside us european commission granted full ethicon franchise achieved sales billion approval prezista combination ritonavir anti increase prior year result growth retroviral medicinal products treatment hiv infection hemostasis meshes biosurgical product lines extended indication include treatmentexperienced sales cordis franchise billion decline adultpatients decline reflects lower sales cypher company submitted applications regulatory approval sirolimuseluting coronary stent due increased global compe four additional compounds golimumab monthly subcu tition decline partially offset performance taneous treatment adults active forms rheumatoid arthri biosense webster neurovascular businesses tis psoriatic arthritis ankylosing spondylitis filed us diabetes care franchise achieved sales billion european union us filings submitted rivaroxa increase prior year growth driven ban oral oncedaily anticoagulant prevention deep sales animas business due new product launches vein thrombosis dvt pulmonary embolism pe patients salesgrowth ultra product lines outside us undergoing hip knee replacement surgery carisbamate vision care franchise achieved sales billion adjunctive treatment partialonset seizures patients years increase prior year sales acuvue ofage older trabectedin known yondelis outside oasys day acuvue moist acuvue oasys us administered combination doxil doxorubicin hcl forastigmatism major contributors growth liposome injection treatment women relapsed orthoclinical diagnostics franchise achieved sales ovarian cancer billion increase prior year resulting pharmaceutical segment sales billion growth immunohematology immunodiagnostics products anincrease change due medical devices diagnostics segment achieved sales operational growth remaining increase related billion representing increase prior year positive impact currency fluctuations us pharmaceutical seg operational growth due positive ment sales werebillion increase international impact currency fluctuations us sales billion pharmaceutical segment sales billion increase increase international sales billion increase included operational growth operations positivecurrency impact relatedto positive impact currency fluctuations medical devices diagnostics segment analysis consolidated earnings medical devices diagnostics segment achieved sales provision fortaxes income billion representing increase prior year operational growth due consolidated earnings provision taxes income positiveimpact currency fluctuations us sales bil increased billion billion compared lion increase international sales billion billion earned contributing billion increase operations positive increase werelower inprocess research development currency impact charges billion higher income divestitures bil depuy franchise achieved sales billion lion higher litigation gains billion versus restructuring increase prior year growth primarily due charges billion writedown natrecor depuys orthopaedic joint reconstruction products including intangible asset billion recorded decrease hipand knee product lines additionally new product launches billion primarily due mitek sports medicine product line contributed growth torestructuring charges writedown natrecor ethicon endosurgery franchise achieved sales bil intangible asset percent sales consolidated earn lion increase prior year growth ings beforeprovision taxes income versus mainly driven harmonic technology business due sections follow highlight significant success newly launched products underlying strength components changes consolidated earnings provision taxes income major medical devices diagnostics franchise sales change dollars millions vs vs depuy ethicon endosurgery ethicon cordis diabetes care vision care orthoclinical diagnostics total prior year amounts reclassified conform current presentation managements discussion analysis results operations financial condition cost products sold selling marketing administrative agreater proportion sales attributable consumer expensescost products sold selling marketing segment higher selling marketing administrative administrative expenses percent sales follows spending additionally company utilized gain asso ciated divestiture professional wound care business sales ofethicon inc fund increased investment spending cost products sold partially offset ongoing cost containment efforts percent point increase prior year increase percent sales cost selling marketing administrative expenses ofproducts sold primarily due impact newly acquired percent point increasedecrease consumer brands increase percent sales prior year selling marketing administrative expenses primarily due impact newly acquired consumer brands partially cost products sold percent sales remained flat offset cost containment efforts tothe prior year change mix businesses higher increase percent sales sales growth consumer business slight sales decline cost products sold due unfavorable product mix pharmaceutical business continues negative impact higher manufacturing costs pharmaceutical consumer cost products sold percent sales segments decrease percent sales selling offset manufacturing efficiencies nonrecurring positive items marketing administrative expenses result negative items increase inthe ofleveraging selling expenses reduction advertising percent sales selling marketing administrative expenses promotional spending primarily due change mix businesses whereby research development expense excluding inprocess research development charges segment business follows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices diagnostics total research development expense percent decreaseincrease prior year research development research development activities afully integrated biopharmaceutical company develops represent significant partofthe companysbusiness markets biosurgical immunotherapyproducts accounted expenditures relate development new products improve million tax iprd charges ment existing products technical support products company recorded charge iprd compliance governmental regulations protection million tax related acquisition conor consumers patients medsystems inc iprd charge included operating reduction pharmaceutical research profit medical devices diagnostics segment development spending primarily due increased efficiencies companyrecorded iprd charges million pharmaceutical research development activities tax related acquisitions consumer healthcare businessof pfizer inc vascular control systems inc ensure med restructuringthe company achieved approximately billion ical inc colbar lifescience ltd hand innovations llc future annual cost savings outlined therestructuring program medical systems sa charge related consumer health announced see note consolidated financial state care business acquired pfizer inc accounted million ments additional details related restructuring tax iprd charges included operating inprocess research developmentin company profit consumer segment iprd charges fol recorded charge inprocess research development iprd lowing acquisitions included operating profit med million beforeand tax related tothe acquisitions amic ical devices diagnostics segment vascular control systems ab surgrx inc healthmedia inc omrix biopharmaceuticals inc privately held company focused developing medical devices inc healthmedia inc privately held company creates web treat fibroids control bleeding obstetric gynecologic based behavior changeinterventions accounted million applications accounted million tax iprd tax iprd charges included operating profit charges ensure medical inc privately held company develops consumer segment iprd charges following devices postcatheterization closure femoral artery acquisitions included operating profit medical accounted million tax iprd charges colbar devices diagnostics segment amic ab swedish developer lifescienceltdaprivately held company specializing reconstruc vitro diagnostic technologies use pointofcare nearpatient tive medicine tissue engineering accounted million settings outside physical facilities clinical laboratory tax ofthe iprd charges hand innovations llc privately accounted million taxof iprd charges surgrx held manufacturer fracture fixation products upper inc privately held developer advanced bipolar tissue sealing extremitiesaccounted million tax iprd system used enseal family devices accounted mil charges futuremedical systems sa privately held company lion tax iprd charges omrix biopharmaceuticals inc johnson johnson annual reportprimarily develops manufactures markets arthroscopic fluid consumer healthcare business pfizer inc integration management systems accounted million tax recorded theiprd charges pharmaceutical segmentin pharmaceutical segment income expense netother income expense net operating profit increased percent sales includes gains losses related sale writedown operating profit increased primary driver certain investments equity securities held johnson johnson improved operating profit due restructuring charges development corporation gains losses disposal million million natrecor intangible asset property plant equipment currency gains losses minority writedown recorded pharmaceutical segment interests litigation settlements liabilities royalty income operating profit decreased percent sales favorable change billion income expense net operating profit decreased resulting mil primarily due increase income lion restructuring charges million natrecor net litigation settlements awards billion gain intangible asset writedown billion divestiture professional wound care business medical devices diagnostics segment operating ethicon inc natrecor intangible asset write profit medical devices diagnostics segment increased billion percent sales operating profit income expense net included charge increased improved operating profit result million tax related natrecor intangible asset ofthe million gain net litigation settlements favorable writedown gain million associated guidant product mix manufacturing efficiencies lower iprd charges acquisition agreement termination fee less associated expenses million versus million additionally included addition also included expenses million restructuring charges recorded associated recording additional product liability reserves operating profit medical devices diagnostics integration costs associated acquisition segment decreased percent sales consumer healthcare business pfizer inc operating profit decreased resulting million iprd charges million restructuring charges operating profit segment included gain associated guidant acquisi operating profits segment business follows tion agreement termination fee less associated expenses percent million segment sales interestincome expenseinterest income decreased dollars millions million due lower rates interest earned despite higher consumer average cash balances cash balance including marketable pharmaceutical securities billion end averaged med devices diagnostics billion compared billion average cash balance total increase average cash balance primarily less expenses allocated duetocash generated operating activities tosegments interest expense increased million due earnings beforeprovision higher debt balance second half company con taxes income verted shortterm debt fixed longterm debtat higher see note tothe consolidated financial statements details interest rates net debt balance end bil amounts allocated segments include interest income expense minority interest lion compared billion end higher debt general corporate income expense balance primarily due purchase com panys common stock ongoing common stockrepurchase operatingprofit program announced july fundacquisitions bysegment interest income decreased million due inbillionsofdollars lower average cash balances decline average cash balance primarily due acquisition consumer consumer healthcare business pfizer inc december pharmaceutical medicaldevices interest expense increased million com anddiagnostics pared toprior year due toahigher average debt balance net debt balance end billion compared billion end higher debt balance due tothe debt associated acquisition con sumer healthcare business pfizer inc common stock repurchase program announced consumer segmentin consumer segment operating profit interest income increased million due increased percent sales operating primarily higher rates interest well higher average profit increased cost synergies lower integration costs cashbalance despite billion common stock repurchase related acquisition consumer healthcare business program increase acquisition activityas compared pfizer inc cost containment initiatives contributed prioryear increased operating profit consumer segment operating interest expense increased slightly compared profit increased due acquisition costs asso due toahigher average debt balance billion ciated consumer healthcarebusinessof pfizer inc tobillion partially offset byadecrease percent sales operating profit increased interest rates iprd expenses million well expenses associated managements discussion analysis results operations financial condition provision taxes incomethe worldwide effective income tax company hedges exposure fluctuations currency rate exchange rates effect certain assets liabilities tax rate increased compared due increases foreign currency entering currency swap contracts taxable income higher tax jurisdictions relative taxable income change spread us foreign interest rates lower jurisdictions addition tax rate benefited companys interest rate sensitive financial instruments would either onetime gain million related business restructuring increase decrease unrealized value companys swap certain international subsidiaries well increases taxable contracts approximately million either scenario matu income lower tax jurisdictions relative taxable income higher rity gain loss swap contract would offset gain tax jurisdictions lower international tax rates certain countries loss underlying transaction therefore would ascompared tothe prior year impact future cash flows company enter financial instruments liquidity capital resources trading speculative purposes company policy entering contracts parties least liquidity cash flows equivalent credit rating counterparties contracts cash cash equivalents billion end major financial institutions significant concentra compared billion end primary sources tion exposure one counterparty management believes cash contributed billion increase versus prior year risk loss remote billion cash generated operating activities company access substantial sources funds billion net proceeds long shortterm debt major numerous banks worldwide september company uses cash capital spending billion acquisitions secured new day year credit facility total credit avail billion dividends shareholders billion able company approximates billion billion repurchase common stock net proceeds exercise expires september billion expires september ofoptions billion interest charged borrowings credit line agree cash flow operations billion result ments based either bids provided banks prime rate billion net earnings billion noncash charges london interbank offered rates libor plus applicable margins related depreciation amortization stock based compensation commitment fees agreement material billion iprd offset increased working capital total borrowings end bil billion net use related changes assets liabilities net lion billion respectivelythe increase borrowings effects acquisitions billion result financing general corporate companycontinued tohave access liquidity purposes continuation common stock repurchase commercial paper market additional details program announced net cash cash current borrowings see note consolidated financial statements marketable securities net debt billion compared net companyanticipates operating cash flows existing debt billion total debt represented total credit facilities access commercial paper markets capital shareholders equity total debt provide sufficient resources fund operating needs total capital shareholders equity per share end compared yearend increase johnson johnson continues tobe one fewindustrial companies triple credit rating access credit commercially favorable terms summary borrowings found note consolidated financial statements contractual obligations andcommitments company contractual obligations primarily lease debt andunfunded retirement plans significant obliga tions satisfy obligations company use cash operations following table summarizes companys contrac tual obligations aggregate maturities ofdecember see notes consolidated financial financing market risk statements details company uses financial instruments manage impact eign exchange rate changes cash flows accordingly company unfunded operating debt retirement entersintoforwardforeign exchange contracts protect value dollars millions leases obligations plans total certain foreign currency assets liabilities hedge future eign currency products costs gains losses contracts offset bythe gains losses underlying transactions appreciation theus dollar december market rates would increase theunrealized value companys forward contracts million conversely depreciation usdollar december market rates would decrease theunrealized value companys forward contracts mil total lion either scenariothe gain losson forwardcontract would amounts include interest expense offset gain loss underlying transaction fore would impact future earnings cash flows tax matters see note consolidated financial statements johnson johnson annual reportshare repurchase dividends sales returns generally estimated recorded based july company announced board directors onhistorical sales returns information products exhibit approved stock repurchase program authorizing company unusual sales return patterns due dating competition orother buy back billion companys common stock marketing matters specifically investigated analyzed repurchase program time limit may suspended partof accounting sales return accruals periods discontinued time shares acquired sales returns allowances represent reserve products available general corporate purposes company funds may returned due expiration destruction field spe share repurchase program combination available cash cific areas product recall returns reserve based historical debt december company repurchased return trends product market percent gross sales aggregate million shares johnson johnson common promotional programs product listing allowances stock current repurchase program cost billion andcooperative advertising arrangements recorded year addition company annual program repurchase incurred continuing promotional programs include coupons shares use employee stock incentive plans volumebased sales incentive programs redemption cost company increased dividend th con consumer coupons based historical redemption experience secutive year cash dividends paid per share byproduct value volumebased incentive programs based compared dividends per share estimated sales volumes incentive period arerecorded per share dividends distributed follows products sold company also earns service revenue copromotion certain products includes sales cus tomers promotional arrangements evaluated determine first quarter theappropriate amounts deferred second quarter addition company enters collaboration arrange third quarter ments contain multiple revenue generating activities fourth quarter revenue arrangements recognized activity per total formed delivered based relative fair value upfront fees received part arrangements deferred recognized january board directors declared regular revenue earned obligation period cashdividend per share payable march reasonably likely changes assumptions used calculate shareholders record february company theaccruals rebates returns promotions anticipated expects continue practice paying regular cash dividends amaterial effect financial statements company currently discloses impact changes assumptions information quarterly annual filing thereis material financial statement impact critical accounting policies estimates tables show progression accrued managementsdiscussion analysis results operations rebates returns promotions reserve doubtful accounts andfinancial condition arebased companysconsolidated reserve cash discounts segment business fiscal financial statements prepared accordance years ended december december accounting principles generally accepted us preparation financial statements requires management make esti consumer segment mates assumptions affect amounts reported rev enues expenses assets liabilities related disclosures balanceat balanceat beginning payments end actual results may may differ estimates dollars millions period accruals period company believes understanding certain key accounting policies estimates essential achieving insight accrued rebates companys operating results financial condition key accrued returns accounting policies include revenue recognition income taxes legal accrued promotions selfinsurance contingencies valuation longlived assets assumptions used todetermine amounts recorded forpensions subtotal employee benefit plans accounting stock options reservefor doubtful accounts reserve cash discounts revenue recognitionthe company recognizes revenue total product sales goods shipped delivered title riskof loss pass customer provisions certain rebates salesincentives trade promotions coupons product returns accrued rebates discounts customers accounted reductions sales accrued returns inthe period related sales recorded accrued promotions product discounts granted based terms arrange subtotal ments direct indirect market participantsas well reserve doubtful accounts asmarket conditions including prices charged bycompetitors reserve cash discounts rebates largest medicaid rebate provision esti mated based contractual terms historical experience trend total analysis projected market conditions various markets includes reservefor customer rebates million december served thecompanyevaluates market conditions products million december recorded contra asset groups ofproducts primarily analysis ofwholesaler thirdparty sellthrough market research data well internally generated information managements discussion analysis results operations financial condition pharmaceutical segment effecton companys results operations cash flows financial position balance balance company adopted fasb interpretation beginning payments end dollars millions period accruals period fin accounting uncertainty income taxesan interpre tation fasb statement interpretation prescribes accrued rebates recognition threshold measurement attribute financial accrued returns statement recognition measurement tax position taken accrued promotions expected taken tax return interpretation also provides guidance derecognition classification matters see subtotal note consolidated financial statements reserve doubtful accounts information regarding income taxes reserve cash discounts december december total cumulative amounts undistributed international earnings approximately billion billion respectively com accrued rebates pany intends continue reinvest undistributed international earnings expand international operations therefore nous accrued returns tax expense recorded respect undistributed accrued promotions portion intended repatriation subtotal reserve doubtful accounts legal self insurance contingenciesthe company records accruals various contingencies including legal proceedings reserve cash discounts product liability cases arise normal course busi total ness accruals based managements judgment includes reserve customer rebates million december theprobability losses applicable actuarially deter million december recorded contra asset mined estimates additionally company records insurance includes million adjustment related previously estimated accrued sales reserves receivable amounts thirdparty insurers recovery probable appropriate reserves receivables medical devices diagnostics segment recorded estimated amounts maynotbe collected balance balance thirdpartyinsurers beginning payments end dollars millions period accruals period longlived intangible assetsthe companyassesses changes economic conditions makes assumptions regarding estimated accrued rebates future cash flows evaluating value companys property accrued returns plant equipment goodwill intangible assets accrued promotions assumptions estimates may change time itmay may necessary company record impairment charges subtotal reserve doubtful accounts employee benefit plansthe companysponsorsvarious retirement reservefor cash discounts pension plans including defined benefit defined contribution total termination indemnityplans cover employees worldwide plans based assumptions discount rate expected return plan assets expected salary increases accrued rebates health care cost trend rates see note consolidated finan accrued returns cial statements details rates effect accrued promotions ratechangewould companys results operations subtotal stock optionsduring fiscal first quarter company reserve doubtful accounts adopted statement financial accounting standards sfas reserve cash discounts r share based paymentthe company applied modi total fied retrospective transition method implement sfas r previously reported financial statements restated includes reserve customer rebates million december million december recorded contra asset accordance provisions sfas r see note includes million adjustment related previously estimated sales rebate reserve information regarding stockoptions company also earns service revenue copromotion cer new accounting pronouncements tain products yearspresented service revenues less refer note consolidated financial statements recently total revenues included salestocustomers adopted accounting pronouncements recently issued accounting income taxesincome taxes recorded based amounts pronouncements yet adopted asof december refundable payable current year include results difference gaap accounting andtax reporting recorded deferred tax assetsor liabilities company esti mates deferred tax assetsand liabilities based current tax regula tions rates changes tax laws rates may affectrecorded deferred tax assets liabilities future management believes changes estimates would haveamaterial johnson johnson annual reporteconomic market factors reporting period one matters could company aware products used environment significant impact companys results operations cash decade policymakers consumers busi flows period nesses expressed concerns therising cost health care see note consolidated financial statementsfor response concerns company longstanding information regarding legal proceedings policy pricing products responsibly period united states weighted average compound annual growth common stock market prices rate ofthe companys net price increases health care products companys common stock listed new york stock prescription overthecounter drugs hospital andprofessional exchange symbol jnj composite market price ranges products us consumer priceindex cpi johnson johnson common stock inflation rates continue effect worldwide econo mies consequently way companies operate inthe face increasing costs company strives maintain profit mar high low high low first quarter gins cost reduction programs productivity improvements periodic price increases second quarter company exposed fluctuations currency exchange third quarter rates change value us dollar compared fourth quarter allforeign currencies company sales income yearend close expense would increased decreased translation foreign sales million income million cautionary factors may affect company facesvarious worldwide health care changes future results may continue result inpricing pressures include health care cost containment government legislation relating tosales annual report contains forwardlooking statements forward promotions andreimbursement looking statements relate strictly historical orcurrent facts changes behavior spending patterns purchasers anticipate results based managements plans sub health care products services including delaying medical ject uncertainty forwardlooking statements may identified procedures rationing prescription medications reducing use words plans expects anticipates frequency physician visits foregoing health care insurance estimates words similar meaning conjunction coverage result current global economic downturn among things discussions futureoperations financial willcontinue impact companys businesses performance companys strategy growth product develop company also operates environment ment regulatory approval market position expenditures become increasingly hostile tointellectual property rights generic forwardlooking statements arebased current expectations drug firms filed abbreviated new drug applications andas future events company guarantee anyforward seeking tomarket generic forms companys key phar looking statement accurate although company believes maceutical products prior expiration applicable patents reasonable expectations assumptions covering products event company successful investors realize underlying assumptions prove inac defending patent claims challenged andafilings curate unknown risks uncertainties materialize actual generic firms introduce generic versions product results could vary materially companys expectations issue resulting potential substantial market share projections investors therefore cautioned place undue revenue losses product information see thedisc relianceon anyforwardlooking statements company ussion litigation filers abbreviated newdrug appli undertake update forwardlooking statements result cations note consolidated financial statements new information future events developments risks uncertainties include general industry conditions legal proceedings andcompetition economic conditions interest rate companyis involved numerous product liability cases currency exchange rate fluctuations technological advances united states many concern alleged adverse reactions newproducts patents attained competitors challenges drugs medical devices damages claimed substantial inherent new product development including obtaining regula companyis confident adequacy thewarnings tory approvals challenges patents us foreign health care andinstructions use accompany products reforms governmental laws regulations trends toward feasible predict ultimate outcome litigation however health carecost containment increased scrutinyof health company believes liability results cases careindustry government agencies product efficacy safety willbe substantially covered existing amounts accrued concerns resulting product recalls regulatory action companys balance sheet underitsselfinsurance program companysreport year ended thirdpartyproduct liabilityinsurance december includes exhibit discussion company also involved number patent trademark additional factors could cause actual results differ lawsuits well investigations incidental toits busi expectations company notes factors permitted ness ultimate legal financial liability company bytheprivate securities litigation reform act respect claims lawsuits proceedings referred estimated anycertainty however companys opinion based examination matters experience todateand discussions counsel ultimate outcome oflegal proceedings net liabilities already accrued companys balancesheet expected tohave material adverse effect companysfinancial condition although theresolution managements discussion analysis results operations financial condition consolidated balance sheets johnson johnson subsidiaries atdecember december dollars millions except share per share data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes goodwill net notes deferred taxes income note assets note total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stockwithout par value authorized unissued shares common stockpar value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes toconsolidated financial statements johnson johnson annual reportconsolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note restructuring note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings basic net earnings per share notes diluted net earnings per share notes see notes toconsolidated financial statements consolidated financial statements consolidated statements equity johnson johnson subsidiaries accumulated treasury comprehensive retained comprehensive common stock stock dollars millions note total income earnings income issued amount amount balance january net earnings cash dividends paid employee compensation andstock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensiveincome balance december net earnings cash dividends paid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income balance december see notes toconsolidated financial statements johnson johnson annual reportconsolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation purchased inprocess research development intangible asset writedown natrecor decreaseincrease deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions increase accounts receivable increasedecrease inventories decreaseincrease accounts payable accrued liabilities increase current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flowsfrom financing activities dividends toshareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flowdata cash paid year interest income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions see notes toconsolidated financial statements consolidated financial statements notes consolidated financial statements summary significant accounting policies eitf issue accounting nonrefundable advance pay principles consolidation ments goods services received use future research consolidated financial statements include accounts development activities issue effective financial statements johnson johnson subsidiaries company inter issued fiscal years beginning december company accounts transactions eliminated adopted company fiscal first quarter issue requires nonrefundable advance payments research description company business segments development capitalized recognized expense company approximately employees worldwide related goods delivered services performed adoption engaged research development manufacture sale eitf didnot significant impact companys abroad range products health care field company results operations cash flows financial position conducts business virtually countries world itspri mary focus products related human health andwellbeing recently issued accounting standards company organized three business segments adopted december consumer pharmaceutical medical devices diagnostics december fasb issued sfas r business combina consumer segment manufactures markets broad range tionsand noncontrolling interests consolidated financial ofproducts used baby care skin care oralcare wound care statementsthese statements aim improve simplify con andwomens health care fields well nutritional overthe vergeinternationally accounting business combinations counter pharmaceutical products products marketed reporting noncontrolling interests consolidated financial general public sold distributors directly inde statements statements effective fiscal years begin pendent chain retail outlets throughout world pharma ning december sfas r signifi ceutical segment includes products following therapeutic cant impact manner companyaccounts areas antiinfective antipsychotic cardiovascular contraceptive future acquisitions beginning fiscal year significant dermatology gastrointestinal hematology immunology neurology changes include capitalization inprocess research devel oncologypain management urology virology products opment iprd expensing acquisition related restructuring aredistributed directly toretailers wholesalers andhealth care pro actions transaction related costs recognition contin fessionals prescription use medical devices diagnos gent purchase price consideration fair value acquisition tics segment includes broad rangeofproducts used principally date addition changes accounting deferred tax asset professional fields byphysicians nurses therapists hospitals valuation allowances acquired income tax uncertainties diagnostic laboratories clinics products include cordis measurement period recognized earnings rather circulatory disease management products depuys orthopaedic adjustment tothe cost acquisition accounting treat joint reconstruction spinal care sports medicine products ment taxes applicable acquisitions thatoccurred prior ethicons surgical care womens health products ethicon endo subsequent adoption sfas r company surgerys minimally invasive surgical products lifescans blood believes adoption sfas sfas glucose monitoring insulin delivery products orthoclinical material effect results operations cash flows diagnostics professional diagnostic products andvistakons financial position disposable contact lenses march fasb issued sfas statement disclosures derivative instruments hedging activitiesan new accounting pronouncements amendment fasb statement enhance disclosure recently adopted accounting pronouncements regarding companys derivative hedging activities september financial accounting standards board improvethe transparency financial reporting statement fasb issued statement financial accounting standards sfas effective fiscal years beginning november fair value measurements statement defines fair value adoption sfas impact companys establishes framework measuring fair value generally results operations cash flows financial position accepted accounting principles expands disclosures fair eitf issue accounting collaborative arrangements value measurements statement effective fiscal first related development commercialization intellectual quarter except nonfinancial assets liabilities recog propertythis issue effectivefor financial statements issued nized disclosed fair value recurring basis forfiscal years beginning december issue effective date fiscal years beginning november addresses income statement classification payments made company adopted sfas fiscal first quarter parties collaborative arrangement adoption impact discussed note eitf expected significant impact february fasb issued sfas fair value companys results operations cash flows financial position option financial assets financial liabilitieswhich permits eitf issue accounting defensive intangible assets entity measure certain financial assets financial liabilities issue applies acquired intangible assets situations fair value sfas effective fiscal year entity intend actively use asset intends companyadopted fiscal first quarter adoption tohold asset toprevent others obtaining access sfas material effect companys asset except intangible assets used research results operations cash flows financial position development activities issue effective fiscal years beginning december adoption eitf expected significant impact companys results operations cash flows financial position johnson johnson annual reportcash equivalents returns reserve based historical return trends product company considers securities maturities three months market percent togross sales less purchased cash equivalents promotional programs product listing allowances cooperative advertising arrangements recorded year investments incurred continuing promotional programs include coupons shortterm marketable securities carried cost approxi volumebased sales incentive programs redemption cost mates fair value investments classified availableforsale consumer coupons based historical redemption experience carried estimated fair value unrealized gains losses byproduct value volumebased incentive programs based recorded component accumulated comprehensive estimated sales volumes incentive period income longterm debt securities company ability recorded products sold company also earns service intent hold maturity carried amortized cost revenue copromotion certain products includes also approximates fair value management determines appropri salestocustomers promotional arrangements evaluated ate classification investment debt equity securities determine appropriate amounts deferred time purchase reevaluates determination addition company enters collaboration arrange balance sheet date thecompany periodically reviews invest ments contain multiple revenue generating activities ments equity securities impairment adjusts invest revenue arrangements recognized activity ments fairvalue decline market value deemed performed delivered based relative fair value upfront tobe thantemporary feesreceived part arrangements deferred recognized revenue earned obligation period property plant equipment depreciation property plant equipment stated cost company shipping handling utilizes straightline method depreciation overthe estimated shipping handling costs incurred million mil useful lives assets lion million respectively included selling marketing administrative expense building building equipment years amount revenue received shipping handling less land leasehold improvements years sales tocustomers periods presented machinery equipment years companycapitalizes certain computer software develop inventories ment costs included machinery equipment incurred inventories stated lower cost market determined inconnection developing orobtaining computer software firstin firstout method internal use capitalized softwarecosts amortized estimated useful lives ofthe software generally range intangible assets goodwill years sfas requires thatgoodwill nonamortizable intangible companyreviewslonglived assets assess recover assets assessed annually impairment company com abilityusing undiscounted cash flows necessary charges pleted annual impairment test fiscal fourth quar forimpairments longlived assets recorded amount ter impairment determined future impairment tests bywhich present value future cash flows less beperformed annually fiscal fourth quarter sooner carrying value assets triggering event occurs intangible assets finite useful lives continue amortized useful lives reviewed impairment revenue recognition company recognizes revenue product sales warranted economic conditions see note goods areshipped delivered title riskof loss pass details intangible assets customer provisions certain rebates sales incentives trade pro motions coupons product returns discounts customers financial instruments accounted reductions sales inthe period related companyfollows provisions sfas accounting sales arerecorded derivative instruments hedging activitiesas amended sfas product discounts granted based terms arrange requires derivative instruments recorded bal ments direct indirect market participants well ance sheet fair value changes fair value derivatives asmarket conditions including prices charged competitors recorded period current earnings comprehensive rebates largest medicaid rebate provision esti income depending whether thederivative designated part mated based contractual terms historical experience trend hedgetransaction ifsothe type hedgetransaction analysis projected market conditions various markets company uses forward exchange contracts manage served thecompany evaluates market conditions products itsexposure variability cash flows primarily related groups ofproducts primarily analysis wholesaler foreign exchange rate changes future intercompany product thirdparty sellthrough market research data well thirdparty purchases raw materials denominated foreign cur internally generated information rency company also uses currency swaps manage currency sales returns generally estimated recorded based risk primarily related borrowings types deriva historical sales returns information products exhibit tives designated cash flow hedges additionally company unusual sales return patterns due dating competition uses forward exchange contracts tooffset exposure certain marketing mattersarespecifically investigated analyzed part foreign currency denominated assets liabilities forward accounting sales return accruals sales returns allowances exchange contracts designated hedges therefore represent reserve products may bereturned due expi changes fair values ofthese derivatives recognized ration destruction field specific areas product recall currently earnings thereby offsetting thecurrent earnings effect related foreign currency assets andliabilities notes consolidated financial statements designation cash flow hedge made entrance income taxes date derivative contract inception derivatives company intends continue reinvest undistributed expected highly effective changes fair value deriva international earnings expand international operations tive designated cash flow hedgeand highly effective fore us tax expense recorded respect recorded accumulated othercomprehensive income undistributed portion intended repatriation december underlying transaction affects earnings reclassified december cumulative amount undistrib earnings account hedged transaction fair uted international earnings approximately billion value derivative instrument ie forward foreign exchange con billion respectively tract currency swap aggregation currency future deferred income taxes recognized tax consequences cash flows discounted present value prevailing market oftemporary differences applying enacted statutory taxrates interest rates subsequently converted us dollar applicable future years differences thefinancial current spot foreign exchange rate reporting tax basis existing assets andliabilities ongoing basis company assesses whether derivative continues highly effective offsetting changes net earnings per share cash flows hedged items derivative isno longer basic earnings per share computed dividing net earnings avail expected highly effective hedge accounting isdiscontinued able common shareholders weighted average number hedge ineffectiveness included current period earnings common shares outstanding period diluted earnings per insignificant share reflects potential dilution could occur securities company documents relationships hedged exercised converted common stock using treasury items derivatives overall risk management strategy stock method includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize use estimates foreign currency exposures impact companys financial preparation consolidated financial statements conformity performance protect companys cash flow adverse accounting principles generally accepted us requires movements foreign exchange rates ensure appropriate management make estimates assumptions affect nessof financial instruments manage enterprise risk amounts reported estimates used accounting sales associated financialinstitutions discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits product liability contingencies intangible asset liability valuations accruals product liability claims recorded undis instance determining annual pension postemployment ben counted basis probable liabilityhas incurred efit costs company estimates rate return plan assets amount liability reasonably estimated based cost futurehealth carebenefits actual results may existing information accruals adjusted periodically may differ estimates additional information becomes available result cost availability factors effective november company annual closing date ceased purchasing thirdparty product liability insurance based company follows concept fiscal year ends ontheavailability prior coverage receivables insurance thesundaynearest tothe end month decembernormally recoveries related product liability claims recorded fiscal year consists weeks every five six years anundiscounted basis probable recovery case fiscal year consists weeks berealized reclassification research development certain prior period amounts reclassified conform research development expenses expensed incurred current year presentation upfront milestone payments made thirdparties connec tion research development collaborations expensed inventories incurred point regulatory approval payments made end inventories comprised thirdparties subsequent regulatory approval capitalized andamortized remaining useful life related product dollars millions amounts capitalized suchpayments included raw materials supplies intangibles net accumulated amortization goods process finished goods advertising costs associated advertising expensed year incurred areincluded selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising bil lion billion billion johnson johnson annual report property plant equipment borrowings end property plant equipment cost components longterm debt follows accumulated depreciation effective effective dollars millions dollars millions rate rate land land improvements zero coupon convertible subordinated buildings building equipment debentures due machinery equipment debentures due construction progress debentures due notes due less accumulated depreciation debentures due notes due debentures due company capitalizes interest expense part cost con notes due struction facilities equipment interest expense capitalized notes due million million gbp gbp million respectively notes due depreciation expense including amortization capitalized b euro b euro interest billion billion debentures due billion respectively debentures due upon retirement disposal property plant equip debentures due ment costs related amounts accumulated depreciation amortization eliminated asset accumulated depre includes industrial revenue bonds ciation accounts respectively difference net asset value proceeds recorded inearnings less current portion rental expense lease commitments rentals space vehicles manufacturing equipment office weighted average effective rate translation rate december data processing equipment operating leases approxi translation rate december mately million million million excess fair value carrying value debt billion billion approximate minimum rental payments required companyhas accesstosubstantial sources funds operating leases haveinitial remaining noncancelable lease numerous banks worldwide september company terms excess one year december secured new day year credit facility total credit avail dollars millions able company approximates billion billion total expires september billion expires september interest charged borrowings credit line agree ments based either bids provided banks prime rate commitments capital leases arenot significant london interbank offered rates libor plus applicable margins commitment fees agreements material employee related obligations company filed shelf registration securities exchange commission became effective march end employee related obligations enables company issue unlimited aggregate dollars millions principal amount debt securities warrants purchase debt pension benefits securities company issued bonds june total postretirement benefits billion general corporate purposes postemployment benefits july alza corporation subsidiary deferred compensation company completed private offering zero coupon convertible subordinated debentures issued total employee obligations priceof per principal amount maturity less current benefits payable theterms debentures holders entitled convert employee related obligations longterm theirdebentures approximately million shares johnsonjohnson stock priceof per share approxi prepaid employee related obligations million mil mately million shares issued december lion respectivelyareincluded assets due voluntary conversions note holders option consolidated balance sheet ofthe holderthe debentures may repurchased company july purchase price equal issue priceplus accreted original issue discount purchase date companyat option mayalso redeem anyor debentures july issue price plus accreted original issue discount notes consolidated financial statements throughout company continued access weighted average amortization periods patents liquidity commercial paper market shortterm borrow trademarks intangible assets years years ings current portion longterm debt amounted approxi respectively amortization expense amortizable assets mately billion end ofwhich billion thefiscalyears ended december december raised commercial paper program remainder repre december million million mil sents principally local borrowing byinternational subsidiaries lion tax respectively certain patents intangible assets aggregate maturities longterm obligations commencing written fair value fiscal years resulting charge included amortization expense dollars millions estimated amortization expense five succeeding years approximates million tax per year substantially amortization expense included cost products sold intangible assets goodwill income taxes end gross net amounts provision taxes income consists intangible assets goodwill dollars millions dollars millions currently payable trademarks nonamortizablegross us taxes less accumulated amortization international taxes trademarks nonamortizablenet patents trademarksgross deferred less accumulated amortization us taxes patentsand trademarksnet international taxes intangiblesgross less accumulated amortization intangiblesnet acomparison income tax expense us statutory rate subtotal intangible assetsgross companys effective tax rate less accumulated amortization isas follows subtotal intangible assetsnet dollars millions goodwillgross us less accumulated amortization international goodwillnet earnings taxes income total intangible assets goodwillgross tax rates less accumulated amortization us statutory rate total intangible assets goodwillnet puertoricoand ireland operations research orphan drug tax credits goodwill december december us state local allocated segment business follows international subsidiaries excluding ireland med dev us manufacturing deduction dollars millions consumer pharm diag total process research goodwill december development iprd acquisitions us tax international income translationother goodwill december effective tax rate acquisitions translationother companyhas subsidiaries manufacturing ireland goodwill december incentive tax rate addition company subsidiaries operat ing puerto rico various tax incentive grants increase inthe tax rate mainly attributed increases taxable income higher tax jurisdictions relative taxable income lower jurisdictions decrease tax rate mainly attrib uted business restructuring ofcertain international subsidiaries resulting onetime benefit million reduced effective tax rate johnson johnson annual reporttemporary differences carry forwards international currency translation follows translation subsidiaries operating nonus dollar cur rencies company determined local currencies international subsidiaries functional currencies except deferred tax deferred tax highly inflationary economies defined dollars millions asset liability asset liability employee related obligations compound cumulative rates inflation ormore past three years substantial portion stock based compensation cash flows local currency depreciation consolidating international subsidiaries balance sheet cur nondeductible intangibles rency effects recorded component accumulated international rd capitalized comprehensive income equity account includes results tax oftranslating balance sheet assets liabilities current reserves liabilities exchange rates except located highly inflationary income reported economies translation balance sheet accounts highly tax purposes inflationary economies reflected operating results miscellaneous international analysis changes capitalized intangibles foreign currency translation adjustments included note miscellaneous us net currency transaction translation gains losses total deferred income taxes included income expense losses million million million respectively difference net deferred tax income per balance sheet net deferred tax included taxes common stockstock option plans onincome balance sheet deferred tax miscella stockcompensation agreements neous us includes current year tax receivables stock options company adopted fin accounting uncertainty atdecember company stockbased compen income taxeseffective january company billion sation plans shares outstanding contracts gross unrecognized tax benefits december companys stock option plans long company classifies liabilities unrecognized tax benefits term incentiveplan nonemployee directors plan related interest penalties longterm liabilities interest expense thecentocor innovasive devices alza inverness scios stock penalties related tounrecognized tax benefits classified option plans options restricted shares income tax expense fiscal year ended december granted plans except longterm companyrecognized million interest expense incentive plan aftertax impact million year ended december compensation cost recorded sfas company recognized million interest expense charged income plans million million interest income aftertax impact million million million total expense total amount accrued interest million income tax benefit recognized income statement share million respectively based compensation costs million million following table summarizes activity related million sharebased compensation unrecognized tax benefits costs capitalized part inventory insignificant periods dollars millions stock options expire years date grant vest beginning year service periods range six months five years increases related current year tax positions options granted average high low prices increases related prior period tax positions companys common stock new york stock exchange date grant longterm incentive plan com decreases related prior period tax positions pany may issue million shares common stock shares settlements available future grants longterm incentive plan lapse statute limitations million end end year unrecognized tax benefits approximately billion atdecember recognized would affect companys annual effective tax rate company conducts business filestax returns numerous countries currently tax audits progresswith number tax authorities us internal revenue service irs completed audit tax years major jurisdictions company conducts business years remain open generally back year jurisdictions remaining open far back company expect total amount unrecognized tax benefits significantly change next twelve months company expect significant pay ment within next twelve months able provide areasonably reliable estimateof timing anyfuture tax payments relating uncertain tax positions notes consolidated financial statements company settles employee stock option exercises following table summarizes stock options outstanding treasury shares treasury shares replenished throughout exercisable december year number shares used settle employee stock optionexercises shares thousandsoutstanding exercisable average average fair value option award estimated date exercise average exercise exercise ofgrant using blackscholes option valuation model uses price range options life price options price assumptions noted following table expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthe money traded johnson johnson options witha life years torical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate average contractual life remaining years expected volatility stock options exercisable december december expected life yrs yrs yrs average price average dividend yield lifeof years average price average life years respectively asummary option activity plan december december december changes restricted share units years ending dates presented company grants restricted share units vesting period ofthree years company settles employee stock issuance aggregate weighted intrinsic treasury shares treasury shares replenished throughout outstanding average value year number shares used employee stock issuances shares thousands shares exercise price dollars millions asummary shareactivityunder plan shares january december options granted options exercised outstanding shares thousands shares options canceledforfeited shares january shares december shares granted options granted shares issued options exercised shares canceledforfeited options canceledforfeited shares december shares december shares granted options granted shares issued options exercised shares canceledforfeited options canceledforfeited shares december shares december shares granted shares issued total intrinsic value options exercised million shares canceledforfeited million million respec shares december tively total unrecognized compensation cost million december million december average fair value restricted share units granted million december weighted average respectively period cost recognized years years using fair market value date grant fair value yearsfor respectively restricted share units discounted dividends paid restricted share units vesting period fair value restricted shareunits settled million million million respectively johnson johnson annual report segments businessand geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices diagnostics united states international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics total less income expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total sales tocustomers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company customer represented total revenues amounts allocated segments include interest income expense minority interest general corporate income expense general corporate includes cash marketable securities includes million million inprocess research development iprd consumer medical devices diagnostics segments respectively includes million fourth quarter net litigation gain comprised million expense consumer segment gain million medical devices diagnostics segment medical devices diagnostics segment also includes million gain divestiture professional wound care business ethicon inc includes million restructuring expense comprised million million million consumer pharmaceutical medical devices diagnostics segments respectively medical devices diagnostics segment includes million iprd pharmaceutical segment also includes million writedown natrecor intangible asset includes million million iprd consumer medical devices diagnostics segments respectively medical devices diagnostics segment also includes guidant acquisition agreement termination fee less associated expenses million longlived assets include property plant equipment net respectively intangible assets goodwill net respectively notes consolidated financial statements accumulated comprehensive income tax effect unrealized gainslosses equity components comprehensive incomeloss consist securities expense million million mil thefollowing lion respectively tax effect related employee benefit plans million million total million respectively tax effect unrealized gains accumulated foreign gains losses gainslosses derivatives hedges losses million currency losses employee derivatives comprehensive gains million losses million dollars millions translation securities benefit plans hedges incomeloss see note additional information relating derivatives january hedging changes currency translation adjustments currently net change due adjusted income taxes relate permanent investments hedging transactions international subsidiaries net amount reclassed net earnings net changes pensions benefit plans company sponsors various retirement pension plans december including defined benefit defined contribution termination changes indemnity plans cover employees worldwide com net change due pany also provides postretirement benefits primarily health care hedging transactions us retired employees dependents net amount reclassed many international employees covered government net earnings sponsored programs cost company significant net changes retirement plan benefits primarily based employees december compensation last three five years retirement changes number years service international subsidiaries net change due plans funds deposited trustees annuities hedging transactions purchased group contracts orreserves provided netamount reclassed companydoes fund retiree health carebenefits net earnings advance right modify plans future net changes company uses date consolidated financial state december ments december december respectively measurement date us international retirement total comprehensive income includes reclassification benefit plans adjustment gains million realized sale equity september statement financial accounting stan securities associated tax expense million dards sfasno employers accounting defined benefit pen total comprehensiveincome includes reclassification sion postretirement planswas issued amends adjustment gains million realized sale equity disclosurerequirements pensions postretirement securities associated tax expense million benefits statement amendment fasb statements total comprehensiveincome includes reclassi r incremental effect applying fasb fication adjustment gains million realized sale billion reduction shareholder equity net equity securities associated tax expense million deferred taxes johnson johnson annual reportnet periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements net periodic benefit cost net periodic benefit cost attributable us retirement plans million million million respectively amounts expected recognized net periodic benefit cost life expectancy amortization gains losses coming year companys defined benefit retirement us benefit plans determined using corridor plans postretirement plans greater market value assets projected benefit obliga tion total unamortized gains losses excess corridor dollars millions amortized average remaining future service amortization net transition obligation prior service costsbenefits us pension plans amortization net actuarial losses amortized remaining future service plan participants amortization ofprior service cost time plan amendment prior service costbenefit us benefit plans amortized average remaining unrecognized gains losses us pension plans amor service full eligibility age plan participants time tized average remaining future service plan plan amendment plans active employees amortized average weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year retirement plans benefit plans dollars millions us benefit plans discount rate expected longterm rate return plan assets rateof increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rateofincrease compensation levels companys discount rates determined considering following table displays assumed health care cost trend current yield curves representing high quality longterm fixed rates individuals income instruments resulting discount rates consistent health care plans duration plan liabilities health care cost trend rate assumed next year expected longterm rate return plan assets assump ratetowhich cost trend rate assumed tion determined using building block approach considering decline ultimate trend historical averages real returns asset class incertain year rate reaches ultimate trend rate countries wherehistorical returns meaningful considera tion given local market expectations longtermreturns aonepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation notes consolidated financial statements following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return loss plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amountsrecognized accumulated comprehensive income consist following netactuarial gain loss prior servicecostcredit unrecognized net transition asset total tax effects accumulated benefit obligations end ofyear changes plan assets benefit obligations recognized comprehensive income net periodic benefit cost netactuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost effectofexchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company fund certain plans funding required billion projected benefit obligation billion underfunded status billion accumulated benefit obligation fiscal years relates unfunded pension plans plans accumulated benefit obligations excess plan assets consist following retirement plans dollars millions accumulated benefit obligation projected benefit obligation plan assets fair value johnson johnson annual reportstrategic asset allocations determined country based nonmature plans longterm strategic asset allocations nature liabilities considering demographic composi consistent types plans emphasis placed diversi tion plan participants average age years service fying equities broad basis combined currency matching active versus retiree status companys plans considered fixed income assets following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plansgross medicare rebates benefit plansnet company contributed million million international plans funded accordance local toits us international pension plans respectively addition regulations additional discretionary contributions made company funded million us plans first two deemed appropriate meet longterm obligations months plansfor certain plans funding common practice fund congress passed pension protection act ing provides economic benefit consequently company act amended employee retirement income security act several pension plans funded erisa plan years beginning established new minimum funding standards us employer defined benefit plans company plans continue fund us defined benefit plans comply act following table displays projected future minimum contributions companys us international unfunded retirement plans amounts include anydiscretionary contributions company may elect make future dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans companysretirement plan asset allocation end target allocations follows percent target plan assets allocation us retirement plans equity securities debtsecurities total plan assets international retirement plans equity securities debt securities real estate total plan assets companys benefit plans unfunded except us fair value johnson johnson common stock directly lifeinsurance contract assets million million held plan assets million total plan assets december december respectively december million total plan assets atdecember notes consolidated financial statements cash cash equivalents marketable securities december december amortized unrealized estimated amortized unrealized estimated dollars millions cost gainslosses fair value cost gainslosses fair value current investments cash government securities obligations corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities noncurrent investments marketable securities asof december current marketable securities consist eligible total company matching contributions plans million million million government securities million million million obligations corporate debt securities time deposits respectively mergers acquisitions divestitures december current marketable securities con sist million million government securities certain businesses acquired million cash obligations corporate debt respectively million liabilities assumed acquisitions accounted purchase method accordingly results operations included financial statements concentration credit risk respective dates acquisition company invests excess cash deposits major acquisitions included amic ab privately held banks throughout world highquality money market swedish developer vitro diagnostic technologies use instruments company policy making investments pointofcare nearpatient settings beijing dabao cosmetics onlywith commercial institutions least co ltd company sells personal care brands china equivalentcredit rating surgrx inc privately held developer advanced bipolar tissue sealing system used enseal family devices financial instruments healthmedia inc privately held companythat creates web derivative instruments recorded balance sheet basedbehavior change interventions lge performance systems fairvalue see note additional details inc privately held company known human performance insti december balanceof deferred net gains tute develops sciencebased training programs toimprove onderivatives included accumulated comprehensive employee engagement productivity omrix biopharmaceu income million aftertax additional information see ticals inc fully integrated biopharmaceutical company note company expects substantially amount develops markets biosurgical immunotherapy products reclassified earnings next months result excess purchase price estimated fair value oftransactions expected occur period tangible assets acquired amounted million maximum length time company hedging trans assigned identifiable intangible assets residual recorded action exposure months amount ultimately realized goodwill approximately million identified earnings differ foreign exchangerates change realized value iprd associated acquisitions omrix biophar gainsand losses ultimately determined actual exchange maceuticals inc amic ab surgrx inc healthmedia inc ratesat maturity thederivative derivative gainslosses initially iprd charge related acquisition omrix biophar reported component comprehensive income maceuticals inc million associated standalone reclassified earnings period forecasted combination biosurgical technologies used achieve hemosta transactions affect earnings sis value iprd calculated using cash flowprojec fiscal years ended december december tions discounted risk inherent projects probability december net impact hedge ineffective success factors ranging used reflect inherent ness transactions qualifying hedge accounting dis clinical regulatory risk discount rate applied continuanceof hedges tothe companys financial statements end fiscal year outstanding shares wasinsignificant common stock omrix biopharmaceuticals inc tendered refer note disclosures movements accumulated stockholders excluding shares tendered subject guar comprehensive income anteed delivery procedures outstanding shares com mon stock tendered december company completed acquisition omrix biopharmaceuticals inc savings plan iprd charge related acquisition amic ab company voluntary k savings plans designed million associated pointofcare device cast enhance existing retirement programs covering eligible employ chip technologies value iprd calculated using ees company matches percentage employees contri cash flowprojections discounted risk inherent butions consistent provisions plan heshe projects discount rate applied johnson johnson annual reportthe iprd charge related acquisition surgrx inc unaudited pro forma results million associated vessel cutting sealing surgical year ended devices value iprd calculated using cash flow pro december shares millions except per share data jections discounted risk inherent projects probability net sales ofsuccess factors ranging used reflect inher net earnings ent clinical regulatory risk discount rate applied diluted net earnings per share iprd charge related acquisition healthmedia inc million associated primarily process iprd charge related acquisition consumer enhancements software technology value iprd healthcare business pfizer inc million pretax wascalculated using cash flow projections discounted risk basis million aftertax basis isprimarily associ inherent projects probability success factor ated rights obtained switch zyrtec us used reflect inherent risk discount rate applied prescription overthecounter status switch approved certain businesses acquired million cash fda effective november value iprd million liabilities assumed acquisitions calculated using cash flow projections discounted forthe risk accounted purchase method accordingly inherent projects probability success factor results operations included financial statements wasused reflect inherent regulatory risk acquisition respective dates acquisition dateand discount rate applied acquisitions included conor medsystems inc company completed analysis integration plans cardiovascular device company new drug delivery technology pursuant company incurring costs primarily related robert reid inc japanese orthopedic product distributor elimination certain duplicate selling general andadminis mayas mom inc social media company trative functions two companies areas excess purchase price estimated fair value globalbusiness services corporate staff gotomarket support oftangible assets acquired amounted million well excess manufacturing capacity beenassigned identifiable intangible assets residual addition tothe acquisition consumer healthcarebusi recorded goodwill approximately million ness pfizer inc acquisitions included animas corporation identified value iprd associated acquisition aleading maker insulin infusion pumps related products conor medsystems inc hand innovations llc privately held manufacturer offracture iprd chargerelated acquisition conor fixation products upper extremities future medical systems medsystems inc million associated research sa privately held company primarily develops manufac related discovery application stent technology tures markets arthroscopic fluid management systems vascu thevalue iprd calculated using cash flowprojections lar control systems inc privately held company focused discounted risk inherent projects discount rate developing medical devices treat fibroids control bleeding applied obstetric gynecologic applications groupe vendme sa certain businesses acquired billion cash privately held french marketer adult baby skin care products billion liabilities assumed acquisitions colbar lifescience ltd privately held company specializing accounted purchase method accordingly reconstructivemedicine tissue engineering ensuremedical results operations included financial statements inc privately held company develops devices post respectivedates acquisition except noted catheterization closure femoral artery december company completed excluding acquisition consumer healthcare business acquisition consumer healthcare business pfizer inc pfizer inc excess purchase price estimated fair apurchase price billion cash operating results value tangible assets acquired amounted million theconsumer healthcare business pfizer inc reported assigned identifiable intangible assets companys financial statements beginning residual recorded goodwill approximately million results subsequent acquisition date significant identified value iprd primarily associated acquisi order toobtain regulatory approval transaction tions hand innovations llc future medical systems sa vascular company agreed divest certain overlapping businesses control systems inc colbar lifescience ltd ensure medical inc company completed divestiture zantac product iprd charge related acquisition hand ondecember divestitures kaopectate innovations llc million associated fracture unisom cortizone balmex act products repair technologies value iprd calculated using january cash flowprojections discounted risk inherent following table provides proforma results operations projects probability success factors ranging forthe fiscal year ended december consumer used reflect inherent clinical regulatory risk discount healthcare business pfizer inc acquired begin rate applied ning period presented pro forma results include iprd charge related acquisition future medical effect divestitures certain purchase accounting adjustments systems sa million associated nextra estimated changes depreciation amortization duo pump product technologies value iprd expense acquired tangible intangible assets however calculated using cash flow projections discounted risk inher pro forma results include anticipated cost savings ent projects probability success factor effects planned integration consumer healthcare technologies used reflect inherent clinical regulatory risk businessof pfizer inc accordingly amounts necessar discount rateapplied ily indicative results acquisition occurred iprd charge related acquisition vascular control dates indicated may occur future systems inc million associated flostat system technology value iprd calculated using cash flow projections discounted risk inherent projects notes consolidated financial statements aprobability success factor used reflect inherent alleged overpayments risperdal several seek certifi clinical regulatory risk discount rate applied cation classactions case brought attorney general iprd charge related acquisition colbar lifescience ofwestvirginia based claims alleged consumer fraud ltd million associated evolence family toduragesic well risperdal janssen found liable products biodegradable dermal fillers value onmotion damages likely assessed less iprd calculated using cash flow projections discounted million janssen intends seek appeal risk inherent projects probability success factors ranging numerous claims lawsuits united states relating used reflect inherent clinical regulatory tothe drug propulsid withdrawn general sale risk discount rate applied companys janssen subsidiary resolved iprd charge related acquisition ensure medical currently enrolled settlement programs aggregate cap inc million associated femoral artery million litigation concerning propulsid pending closure device value iprd calculated using cash canada class action persons alleging adverse flow projections discounted risk inherent projects reactions drug certified aprobability success factor used reflect inherent clinical regulatory risk discount rate applied affirmative stent patent litigation exception consumer healthcare business patent infringement actions tried delaware federal district pfizer inc supplemental pro forma information court late cordis corporation cordis subsidiary per sfas business combinationsand sfas johnson johnson obtained verdicts infringement patent goodwill andother intangible assetsis provided impact validity damage awards boston scientific corporation aforementioned acquisitions material effect boston scientific medtronic ave inc medtronic based companys results operations cash flows financial position anumber cordis vascular stent patents december exception divestiture professional jury damage action boston scientific returned ver wound care business ethicon inc resulted gain dict million jury medtronic action returned million tax recorded income expense verdict million court appeals federal circuit net divestitures upheld liability cases september material effect companys results operations cash flows thedistrict courtentered judgments including interest financial position amounts million million boston scientific medtronic respectivelymedtronic paid million octo ber representing judgment net amounts exchanged legal proceedings settlement number litigations companies product liability net settlement million recorded credit companys subsidiaries involved numerous product income expense net consolidated statement earn liability cases united states many concern alleged ings million judgment boston scientific adverse reactions todrugs medical devices damages reflected financial statements boston scientific claimed aresubstantial companyis confident appealed judgments amounts received adequacy warnings instructions use accompany cordis also two arbitrations medtronic seeking products feasible topredict ultimateoutcome royalties sale stent products introduced medtronic litigation however company believes product liabil subsequent todecember pursuant toa crosslicense ity results cases substantially covered exist agreement cordis medtronic hearing first ing amounts accrued companys balance sheet arbitrations take place march available thirdparty product liability insurance january cordis filed patent infringement action multiple products johnson johnson subsidiaries sub boston scientific delaware federal district court accus ject tonumerous product liability claims lawsuits including ing express taxus liberte stents infringing ortho evra risperdal duragesic cypher stent palmaz patent expired november liberte stent charit artificial disc approximately also accused infringing cordis gray patent expires claimants pending lawsuits claims regarding injuries june jury found express taxus allegedly due ortho evra respect risperdal liberte stents infringed palmaz patent liberte respect tocharit respect tocypher stent also infringed gray patent boston scientific appealed respect duragesic claimants seek substantial us court appeals federal circuit compensatory available punitive damages cordis filed several lawsuits new jersey federal district respect risperdal attorneys general eight courtagainst guidant corporation guidant abbott laboratories states office general counsel commonwealth inc abbott boston scientific medtronic alleging pennsylvania filed actions seeking reimbursement medicaid xiencev abbott promus boston scientific endeavor public funds risperdal prescriptions written offlabel medtronic drug eluting stents infringe several patents owned use compensation treating citizens alleged adverse reac licensed cordis october cordis filed suit tions risperdal civil fines penalties punitive damages boston scientific delaware federal court accusing taxus reliefthe attorneygeneral texas joined qui tam action liberte stent infringing gray patent state seeking similar relief certain actions also seek injunctive relief relating promotion risperdal attor patent litigation various neys general states indicated potential johnson johnson subsidiaries interest pursuing similar litigation companys janssen products various johnson johnson subsidiaries subsidiary orthomcneiljanssen pharmaceuticals inc subject various patent lawsuits outcomes could omjpi obtained tolling agreement staying running potentially adversely affect ability subsidiaries statuteof limitations theyinquireinto issues addition six cases filed union health plans seeking damages johnson johnson annual reportsellthose products require payment past damages appeal dutch supreme court october boston scientific future royalties prevailed nullity action challenging validity kastenhofer july jury federal district court delaware found patent filed cordis germany cordis appealed substantive cordis cypher stent infringed boston scientifics ding hearings scheduled french italian actions patent cordis cypher bx velocity trial boston scientifics us case based kastenhofer stents also infringed boston scientifics jang patent jury patent federal district court california concluded october also found patents valid boston scientific seeks sub jury finding patent invalid jury also stantial damages injunction actions cordis appealed found cordis counterclaim sale boston scientific january court appeals federal circuit ofits balloon catheters stent delivery systems infringe cordis held ding patent invalid expected boston scientific fontirroche patent court denied boston scientifics post move reconsideration appeal jang patent case still trial motions considering appropriate remedy pending judgment upheld remanded trial futureinfringement issues damages injunctive relief may centocor inc cobi filed lawsuit germany boston scientific several actions based genentech inc genentech inus district court central ding patents pending cordis cypher stent cordis district california seeking invalidate cabilly ii patent successful actions trial level boston scientific priorto filing suit centocor asublicense patent appealed boston scientific brought actions belgium nether celltech licensed genentech remicade lands germany france italy kastenhofer patent hadbeen paying royalties celltech centocor terminated purports cover twolayer catheters used deliver thatsublicense stopped paying royalties genentech filed cypher stent enjoin manufacture sale allegedly counterclaim alleging remicade infringes cabilly ii patents infringing catheters countries recover damages deci manufacture remicade ustekinumab golimumab sion lower court netherlands boston scientifics favor reopro infringe various patents relating purification reversed appeal april boston scientific filed antibodies madethrough recombinant dna techniques following chartsummarizes various patent lawsuits concerning products johnson johnson subsidiaries yet proceed trial jj plaintiff product company patents patent holder court trial date date filed twolayer catheters cordis kastenhofer boston scientific corp multiple european contact lenses vision care nicolson ciba vision md fl cypher stent cordis wall wall ed tx cypher stent cordis bonutti marctec sd il cypher stent cordis saffran saffran ed tx stentcatheter delivery systems cordisethicon schock cardio access llc ed tx listerine tooth whitening strips mcneilppc sagel procter gamble wd wi blood glucose meters strips lifescan wilsey roche diagnostics de remicade ustekinumab centocor cabilly ii genentech cd ca golimumab reopro trial date scheduled litigation filers abbreviated new drug noninfringement invalidity unenforceability patents applications andas event subsidiary company involved success following chart indicates lawsuits pending generic firms ful actions statutory month stay expires filed abbreviated newdrug applications andas seeking aruling district courtis obtained firms involved tomarket generic forms products sold various subsidiaries ability upon fda approval introduce generic versions company prior expiration applicable patents covering product issue resulting substantial market share products andas typically include allegations revenue losses product companys subsidiary notes consolidated financial statements asnoted following chart month stays expired expire respect anda challenges regarding various products brand name patentnda generic trial date month product holder challenger court date filed stay expiration concerta mcneilppc andrx de none mg controlled alza release tablet levaquin mg tablet orthomcneil lupin nj ortho tricyclen lo orthomcneil barr nj mg mg mg mg watson nj mg mg razadyne janssen teva de mylan de dr reddys de purepac de barr de alphapharm de razadyne er janssen barr nj none sandoz nj none kv pharma nj ultram er mg tablet orthomcneil par de ultram er mg tablet orthomcneil impax de janssen trial datetobe scheduled action barr pharmaceuticals inc barr regarding stayed pending appeal delaware decision litigation ortho tricyclen lo january companys barr kv sandoz razadyne er formulation patent subsidiary ortho womens health urology division isproceeding barr received fda approval ofits product orthomcneiljanssen pharmaceuticals inc barr agreed haslaunched risk anonbinding term sheet settle litigation settlement action lupin pharmaceuticals inc lupin discussions arestill underwaythe trial court postponed regarding andaconcerning levaquin lupin contends january trial without setting new trial date united states patent trademark office improperly granted october companys subsidiary ortho apatent term extension patent orthomcneil mcneiljanssen pharmaceuticals inc omjpi filed suit federal orthomcneiljanssen pharmaceuticals inc omjpi licenses district court new jersey watson laboratories inc daiichi pharmaceuticals inc daiichi lupin alleges watson response watsons anda regarding ortho activeingredient levaquin subject prior marketing tricyclen lo therefore eligible patent term extension lupin action barr alphapharm respect totheir concedes validity product would violate patent anda challenges razadyne patent janssen licenses marketed prior expiration original patent term fromsynaptech inc synaptech fourday nonjury trial held ultram er actions orthomcneil omjpi filed federal district court delaware may august lawsuits different dosages par pharmaceuticals courtheld patent invalid inc par pharmaceuticals companies inc par may june enabled janssen synaptech appealed decision october two tramadol er formulation patents owned since courts decision three generic companies received purdue pharma products lp purdue napp pharmaceutical final approvals products launched risk pend group ltd napp omjpi also filed lawsuits different ing appeal additional generic approvals launches could occur dosages impax laboratories inc impax tramadol er time formulation patent owned purdue napp august action mcneilppc inc andrx corporation november purdue napp biovail laboratories interna andrx respect anda challenge concerta tional srl biovailthe nda holder joined coplaintiffs patents fiveday nonjury trial held federal district lawsuits par impax courtin delawarein december court yet issue ruling action average wholesale price awp litigation razadyne er cases lawsuit filed johnson johnson several pharmaceutical subsidiaries barron razadyne use patent janssen licenses along numerous pharmaceutical companies defen synaptech june razadyne er formulation dants series lawsuits state federal courts involving patent march lawsuits different dosages allegations pricing marketing certain pharmaceutical werefiled kv pharmaceutical company kv products amounted fraudulent otherwise actionable conduct razadyne er formulation patent december june among things companies allegedly reported suit filed sandoz razadyne use patent aninflated average wholesale price awp drugs issue janssen licenses synaptech may manyof cases federal actions stateactions razadyne er formulation patent june september removed federal court consolidated pretrial pur abovediscussed delaware decision invalidating poses multidistrict litigation mdl federal district court razadyne use patent resulted entry judgment barr bostonmassachusetts plaintiffs cases include patent case sandoz patent classes private persons entities paid portion johnson johnson annual reportpurchase drugs issue based awp state government court appeals ruled plaintiffs appeal denial class entities made medicaid payments drugs issue based certification untimely plaintiffs engaged awp discovery individual plaintiffs claims mdl court identified classes massachusettsonly pri march depuy orthopaedics inc depuy vate insurers providing medigap insurance coverage private johnson johnson subsidiary received subpoena payers physicianadministered drugs payments usattorneys office district new jersey seeking records based awp class class national class indi concerning contractual relationships depuy surgeons viduals made copayments physicianadministered drugs surgeonsintraining involved hip knee replacement covered medicare class trial two massachusetts reconstructive surgery investigation resolved depuy class actions concluded mdl court december four leading suppliers hip knee implants late june mdl court issued posttrial rulings dismiss september agreements us attorneys office ing johnson johnson defendants case regarding district new jersey settlements include month claims classes subsequently class well deferred prosecution agreement dpa acceptance com ruling subject pending appeal awp cases brought pany monitor assure compliance dpa various attorneys general proceeded trial respect four five companies payment settlement monies manufacturers cases including johnson johnson subsidiaries entry five year corporate integrity agreements depuy paid expected set trial andthereafter million asits settlement november attorney gen eral commonwealth massachusetts issued civil inves tigative demand depuy seeking information regarding financial injuly centocor cobi johnson johnson sub relationships number massachusettsbased orthope sidiary received request voluntarily provide documents dic surgeons providers depuy relationships information criminal division us attorneys office publicly disclosed depuy pursuant dpa february district new jersey connection investigation vari depuy received written request information ous centocor marketing practices subsequent requests docu us senate special committee aging followup earlier ments received us attorneys office inquiries concerning number aspects dpa companyand centocor responded requests july scios inc scios johnson johnson sub documents information sidiary received subpoena us attorneys office district december orthomcneil nowomjpi received massachusetts seeking documents related tothe sales mar subpoena us attorneys office boston massachusetts keting natrecor scios responding subpoena early seeking documents relating marketing including alleged august scios advised investigation would label marketing drug topamax topiramate additional handled bythe us attorneysofficefor northern district subpoenas documents received current california san francisco additional requests documents mer employees testified grand jury discussions received responded former current scios underway effort resolve matter whether agreement employees testified grand jury san francisco reached terms uncertain september johnson johnson received subpoena january janssen omjpi received subpoena us attorneys office district massachusetts seeking officeof inspector general us office person documents related tosales marketing eight drugs omni nel management seeking documents concerning sales market care inc manager pharmaceutical benefits longterm care ing payments physicians connection sales facilities johnson johnson subsidiaries involved responded marketing clinical trials risperdal risperidone subpoena several employees companys pharmaceutical documents subsequent also subsidiaries subpoenaed testify grand jury requested additional subpoena seeking information mar connection investigation keting andadverse reactions risperdal received november amgen filed suit hoffmann us attorneys office eastern district pennsylvania laroche inc roche us district court district november subpoenas seeking testimony various wit massachusetts seeking declaration roche product cera nesses grand jury also received janssen roche indicated would seek introduce cooperating responding subpoenas united states infringes number amgen patents concerning september ortho biotech inc cobi received epo amgen licenses epo sale united states ortho asubpoena us office inspector generals denver biotech cobi nondialysis indications trial action colorado field office seeking documents directed salesand concluded october verdict amgens favor finding marketing procrit epoetin alfa tothe present patents valid infringed judgeissued preliminary well dealings us oncology inc healthcare services injunction blocking cera launch said considering network oncologists ortho biotech cobi responded modifying injunction grant roche compulsory license tothe subpoena would allowit launch us paid percent royalty september plaintiffs employment discrimination ina subsequent decision district judge indicated would litigation initiated company federal district grant roche compulsory license court new jersey moved certify class african american february johnson johnson received subpoena hispanic salaried employees company affiliates us securities exchange commission sec requesting docu us employed time november ments relating participation several johnson johnson present plaintiffsseek monetary damages period subsidiaries united nations iraq oil food program present including punitive damages equitable subsidiaries cooperating sec us department relief court denied plaintiffs class certification motion justice doj producing responsive documents december motion reconsideration april plaintiffssought toappeal decisions april notes consolidated financial statements inseptember janssen omjpi received sub inmarch company received letter request poena attorney general state california seeking attorney general state michigan request seeks documents regarding sales marketing sideeffects documents information relating nominal price transactions risperdal aswell interactions state officials regarding company responding request cooperate states formulary medicaidreimbursed drugs janssen inquiry omjpi responded thesubpoena injune johnson johnson received subpoena february johnson johnson voluntarily disclosed united states attorneys office district massachusetts tothe doj sec subsidiaries outside united states relating marketing biliary stents companys cordis believed made improper payments connection subsidiary cordis cooperating responding subpoena sale medical devices two smallmarket countries inseptember multilan ag indirect subsidiary payments may fall within jurisdiction foreign corrupt scheringplough corporation commenced arbitration practices act fcpa course continuing dialogues janssen pharmaceutica nv alleged wrongful termination agencies issues potentially rising level fcpa viola agreement relating payments connection termination tions additional markets brought attention certain marketing rights multilan seeks declaratory relief agencies company company provided con specificperformance damages multilan alleges damages tinue provide additional information doj sec exceed million parties process selecting cooperate agencies reviews matters law enforce anarbitral tribunal ment agencies number countries also pursuing recent years company received numerous requests investigations matters voluntarily disclosed company variety united states congressional committees pro doj sec discussions underway effort resolve duce information relevant ongoing congressional inquiries matters iraq oil food matter referenced companys policy cooperate inquiries produc whether agreement reached terms uncertain ing requested information march company received separate subpoenas respect matters company us attorneys office philadelphia us attorneys subsidiaries vigorously contesting allegations asserted office boston us attorneys office san francisco otherwise pursuing defenses maximize subpoenas relatetoinvestigations three offices referenced prospect success company subsidiaries involved concerning respectively sales marketing risperdal matters continually evaluate strategies managing byjanssen nowomjpi topamax orthomcneil mattersand whereappropriate pursue settlements omjpi natrecor scios subpoenas request informa resolutions best interest company tion regarding companys corporate supervision oversight company also involved number patent three subsidiaries including sales marketing trademark lawsuits incidental toits business ulti drugs company responded requests addition mate legal financial liability company respect us attorneys office boston issued subpoenas grand claims lawsuits proceedings referred esti jury testimony several employees johnson johnson mated certainty however companys opinion based may new york state attorney general issued examination matters experience date dis subpoena seeking information relating marketing safety cussions counsel ultimate outcome legal proceedings procrit company responding requests net liabilities accrued companys balance sheet april companyreceived two subpoenas expected tohave material adverse effect companys finan theoffice attorney general state delaware cial condition although resolution reporting period one subpoenas seek documents information relating nominal matters could significant impact pricing agreements purposes subpoenas nominal pricing companys results operations cash flows period agreements defined agreements company agreed provide pharmaceutical product less ten percent theaverage manufacturer price product companyresponded requests january european commission ec began industrywide antitrust inquiry concerning competitive conditions within pharmaceutical sector sector inquiry based specific allegation company vio lated ec competition law inquiry began unannounced raids substantial number pharmaceutical companies throughout europe including johnson johnson affiliates march ec issued detailed questionnaires approximately companies including johnson johnson affiliates november ec issued preliminary report summarizing findings final report expected june july johnson johnson annual report earnings per share capital treasury stock following reconciliation basic net earnings per shareto changes treasury stock diluted net earnings per share fiscal years ended december december december amounts millions except treasury stock treasury stock number shares thousands shares amount shares millions except per share data balance january basic net earnings per share employee compensation stock option plans average shares conversion subordinated debentures outstandingbasic repurchase common stock potential shares exercisable balance december stock option plans employee compensation stock option plans less shares repurchased conversion subordinated debentures treasury stock method repurchase common stock convertible debt shares balance december adjusted average shares outstandingdiluted employee compensation stock option plans diluted net earnings per share conversion subordinated debentures repurchase common stock diluted net earnings per share calculation includes dilutive balance december effect convertible debt offset related reduction interest expense million tax years aggregate shares common stock issued approximately million shares end diluted net earnings per share excludes million million cash dividends paid per share compared million shares underlying stock options dividends per share per share respectively exercise price options greater average market value would result antidilutiveeffect diluted earnings per share selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions exceptper share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share second quarter includes aftertax charge million iprd fourth quarter includes aftertax charge million iprd million aftertax income net litigation million aftertax gain divestiture professional wound carebusiness ethicon inc gain divestiture professional wound care business ethicon inc reinvested business first quarter includes aftertax charge million iprd third quarter includes aftertax charge million restructuring fourth quarter includes aftertax charge million natrecor intangible asset writedown onetime tax gain million restructuring lower tax rate due increases taxable income lower tax jurisdictions relative taxable income higher tax jurisdictions notes consolidated financial statements restructuring fair value measurements third quarter company announced restructuring fiscal first quarter company adopted initiatives effort improve overall cost structure sfasno fair value measurementsexcept nonfinancial action taken offset anticipated negative impacts associ assets liabilities recognized disclosed fair value non ated generic competition pharmaceutical segment recurring basis effective date fiscal years beginning challenges drugeluting stent market companys phar november sfas defines fair value estab maceuticals segment reduced cost base consolidating lishes framework measuring fair value expands disclo certain operations continuing invest recently launched sures fair value measurements products latestage pipeline new products cordis fiscal first quarter company adopted franchise moved integrated business model sfas fair value option financial assets financial address market changes underway drugeluting stents liabilitiessfas permits company measure certain better serve broad spectrum patients cardiovascular financial assets financial liabilities fair value company needs reducing cost base program allowed com assessed fair value option made available upon adopting sfas pany accelerate steps standardize streamline certain elected apply fair value option aspects enterprisewide functions human resources financial instruments already recognized fair value finance information technology support growth across sfas defines fair value exit price would business also leveraging scale effectively areas received sell asset paid transfer liability fair value procurement benefit operating companies addition marketbased measurement determined using ally part program company plans eliminate assumptions market participants would use pricing asset approximately positions approximately liability statement establishes threelevel hierarchy havebeen eliminated since restructuring initiative prioritize inputs used measuring fair value levels within announced hierarchy described table level fiscal thirdquarter company recorded highest priorityand level lowest million related pretax charges approximately following table provides summary significant million pretax restructuring charges expected assets liabilities measured fair value require cash payments million restructuring charges december consists severance costs million asset writeoffs million million related leasehold obligations quoted million asset writeoffs relate property plant equip prices ment million intangible assets million active significant assets million markets significant identical observable unobservable following table summarizes severance charges assets inputs inputs associated spending dollars millions december level level level assets dollars millions severance derivativeinstruments severance charge liabilities cash outlays derivativeinstruments reserve balance december cash outlays company uses forward exchange contracts manage reserve balance december exposure variability cash flows primarily related foreign exchange rate changes future intercompany third remaining reserve balance severance expected paid accordance companys plans local laws party purchases raw materials denominated foreign currency company also uses currency swaps manage currency risk additional information restructuring relates primarily related borrowings fair value derivative instru segments see note ments aggregation currency future cash flows dis counted topresent value prevailing market interest rates subsequently converted united states dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect com panys results operations cash flows financial position company significant financial assets liabil ities would require revised valuations sfas arerecognized atfair value subsequent events january company completed acquisition mentor corporation net purchase price billion mentor corporation leading supplier ofmedical products theglobal aesthetic market johnson johnson annual reportreport independent registered public accounting firm shareholders board directors johnson johnson financial reporting assessing risk material weakness exists testing evaluating design operating effec opinion accompanying consolidated balance sheets tiveness internal control based assessed risk audits related consolidated statements earnings statements also included performing procedures considered equity statements cash flows present fairly material necessary inthe circumstances believe audits provide respects financial position johnson johnson sub areasonable basis opinions sidiaries company december december acompanys internal control financial reporting results operations cash flows process designed provide reasonable assurance regarding foreach three years period ended december reliability financial reporting preparation financial conformity accounting principles generally accepted statements external purposes accordance generally theunited states america also opinion company accepted accounting principles companys internal control maintained material respects effective internal control financial reporting includes policies procedures financial reporting december based criteria ipertain maintenance records reasonable detail established internal control integrated frameworkissued accurately fairly reflect transactions dispositions committee sponsoring organizations treadway commis assets company ii provide reasonable assurance trans sion coso companys management responsible actions recorded necessary permit preparation financial financial statements maintaining effective internal control statements accordance generally accepted accounting prin financial reporting assessment effectiveness ciples receipts expenditures company internal control financial reporting included accompany made accordance authorizations management ing managements report internal control financial directors company iii provide reasonable assurance reporting ourresponsibility express opinions finan regarding prevention timely detection unauthorized acquisi cial statements companys internal control financial tion use disposition companysassets could reporting based integrated audits conducted audits amaterial effect financial statements accordance standards public company accounting inherent limitations internal control finan oversight board united states standards require cial reporting may prevent detect misstatements also pro plan perform audits obtain reasonable assurance jections evaluation effectiveness future periods whether financial statements arefree material misstatement subject risk controls may become inadequate whether effectiveinternal control financial reporting ofchanges conditions degree compliance maintained material respects audits financial state policies procedures may deteriorate ments included examining test basis evidence supporting theamounts disclosures financial statements assessing accounting principles used significant estimates made bymanagement evaluating overall financial statement presentation audit internal control financial reporting newyork newyork included obtaining understanding internal control february managements report internal control financial reporting section sarbanesoxley act manage used criteria establishedby committee sponsoring ment required assess effectiveness companys inter organizations treadway commission coso internal nal control financial reporting theendof fiscal year controlintegrated frameworkthese criteria areas report based assessment whether companys ofcontrol environment risk assessment control activities informa internal control financial reporting effective tion communication monitoringthe companys assess management company responsible establishing ment included extensive documenting evaluating testing maintaining adequateinternal control financial reporting design operating effectiveness internal controls companys internal control financial reporting designed financial reporting toprovide reasonable assurance reliability companys based companysprocesses assessment financial reporting preparation external financial state described management concluded december ments accordance generally accepted accounting principles companys internal control financial reporting internal controls financial reporting matter well effective designed inherent limitations therefore internal control effectiveness companys internal control financial reporting determined effective provide financial reporting december audited reasonable assurance respect financial statement prepara pricewaterhousecoopers llp independent registered public tion maynot prevent detect misstatements moreover accounting firm stated report appears herein projections evaluation effectiveness future periods subject tothe risk controls maybecome inadequate ofchanges conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness william c weldon dominic j caruso ofthe companys internal control financial reporting chairman board directors vice president finance ofdecember making assessment company chief executive officer chief financial officer johnson johnson annual report summary operations statistical data dollars millions except per share figures sales customerus sales customerinternational total sales cost products sold selling marketing administrative expenses research expense purchased inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income netearnings percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balancesheet data property plant equipment net additions toproperty plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millionsbasic diluted employees thousands net interest income also included cost materials services category includes taxes income payroll property business taxes includes million tax gain divestiture professional wound care business ethicon inc million tax netfourth quarter litigation gain includes million tax writedown related natrecor intangible asset summary operations statistical datashareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockforperiodsoffiveyears andtenyearsendingdecemberagainstthecumulativetotalreturnofthestandardpoorsstockindexthestandardpoors pharmaceuticalindexandthestandardpoorshealthcareequipmentindexthegraphsandtablesassumethatwasinvested ondecemberanddecemberineachofthecompanyscommonstockthestandardpoorsstockindexthe standardpoorspharmaceuticalindexandthestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested yearcumulative totalshareholderreturn johnsonjohnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr jj sp sppharm sphcequip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex yearcumulative totalshareholderreturn johnsonjohnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr jj sp sppharm sphcequip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex shareholder return performance graphs reconciliation nongaap financial measures tables provided reconcile certain financial disclosures letter shareholders vs vs dollars millions except per share data change change earnings provision taxes income reported purchased inprocess research development iprd net gain fourth quarter litigation restructuring charges natrecor intangible asset writedown guidant acquisition agreement termination fee earnings provision taxes income adjusted net earnings reported purchased inprocess research development iprd net gain fourth quarter litigation restructuring charges natrecor intangible asset writedown international tax gain restructuring guidant acquisition agreement termination fee net earnings adjusted diluted net earnings per share reported purchased inprocess research development iprd net gain fourth quarter litigation restructuring charges natrecor intangible asset writedown international tax gain restructuring guidant acquisition agreement termination fee diluted net earnings per share adjusted dollars millions net cash flows operating activities additions property plant equipment free cash flow company believes investors gain additional perspective underlying business trends results providing free cash flow measure earnings tax net earnings diluted net earnings per share excludes iprd charges special items order eval uateongoing businessoperations nongaap financial measures considered replacements read together comparable gaap financial measures reconciliation nongaap financial measuresprincip al office company required file exhibit dividend reinvestment plan one johnson johnson plaza fiscal year certifica plan allows full partial new brunswick new jersey tions section sarbanesoxley dividend reinvestment additional monthly act signed chief executive officer cash investments per year chief financial officer addition johnson johnson common stock without annual meeting company required submit certifica brokerage commissions service charges annual meeting shareholders take tion signed chief executive officer stock purchases interested place april hyatt regency new york stock exchange within days participating plan need authoriza new brunswick albany street new brunswick following annual meeting shareholders tion form andor information please call new jersey meeting convene copies certifications filed previous computershare trust company na shareholders cordially invited attend years posted companys corporate formal notice meeting proxy statement governance web site future certifications outside us proxy sent shareholders posted promptly upon filing hearing imp aired corporate governance common stock shareholders inquiries regarding copies companys annual report listed new york stock exchange stockrelated matters communicate directly quarterly reports form q stock symbol jnj computershare trust company na current reports form k via telecommunications device tdd securities exchange commission shareholder rela tions contact telephone number service proxy statement annual report steven rosenberg available online wwwjnjcom corporate secretary outside us shareholders without charge upon written request secretary companys registered shareholders wish receive investor relations contact principal address calling electronic notice online access future louise mehrotra annual reports proxy materials instead addition companys vice president investor relations paper copies may register online corporate governance web site wwwcomputersharecomusecomms wwwinvestorjnjcomgovernancecfm wwwcomputersharecomeconsent shareholders see companys transfer gent gistrar employees holding shares one principles corporate governance questions regarding stock holdings johnson johnson savings plans charters audit committee certificate replacementtransfer dividends compensation benefits committee johnson johnson web address changes directed nominating corporate governance company site wwwjnjcom computershare trust company na committee policy business conduct royall street johnson johnson history employees code business canton wwwkilmerhousecom conduct ethics members board directors executive officers blog wwwjnjbtwcom outside us copies documents available wwwcomputersharecom youtube wwwyoutubecomjnjhealth shareholders without charge upon written request secretary companys johnson johnson paper used publication made principal address postconsumer recycled fiber forest stewardship council certified chain custody manufactured green energy credits purchase electricity generated renewableenergy sources wind lowimpact hydro resources following trademark trade names johnson johnson affilia ted companies appear report day acuvue trueye accesswellness aciphexpariet active naturals acuminder acuvue acuvue oasys advantage advantage blackhead eraser animas aveeno aveeno positively ageless beijing dabao cosmetics company blue comet centocor centocor biologics children diabetes cilag ag clean clear codman shurtleff concerta confidence spinal cement system cordis cypher cypher elite dabao depuy depuy mitek depuy orthopaedics depuy spine diabetes juvenil doxil duragesic enseal ethicon ethicon endosurgery evicel evithrom feverfew pfe global pharmaceutical supply chain gription groupe vendome harmonic harmonic ace harmonic synergy healthmedia human performance institute intelence invega janssen cilag johnson johnson johnson johnson consumer companies johnson johnson diabetes institute johnson johnson pharmaceutical research development johnson johnson vision care johnsons le petit marseillais levaquinfloxin lge performance systems lifescan listerine listerine total care mcneilppc meal memory mentor micro grooves minimed paradigm navistar thermocool neosporin neutrogena never stop moving nevo nucynta omrix biopharmaceuticals onetouch onetouch ping onetouch ultralink onetouch ultramini onetouch vita orthoclinical diagnostics orthomcneiljanssen pharmaceuticals ortho biotech products prezista procriteprex purple twilight reach reach ultraclean realize realize mysuccess remicade risperdal risperdal consta sedasys sigma skin id smart stelara surgrx taxotere vision care institute topamax trilock tylenol vitros zeftera zevtera zyrtec zyrtecd following trademark trade names comp anies also appear report american diabetes association basilea pharmaceutica ltd bayer healthcare ag beijing organizing committee games xxix olympiad china qin shi huang terracotta army museum forest stewardship council global business coalition hivaids tuberculosis malaria grnenthal health care notification network international olympic committee ioc insead interphex ispe minimed paradigm medtronic minimed inc mothersmothers national psoriasis foundation pharmaceutical processing pharmamar project hope sk holdings co ltd unaids unicef us food drug administration velcade millennium takeda oncology company corporate shareholder informationour c r e believe first responsibility doctors nurses patients mothers fathers others use products services meeting needs everything must high quality must constantly strive reduce costs order maintain reasonable prices customers orders must serviced promptly accurately suppliers distributors must opportunity make fair profit responsible employees men women work us throughout world everyone must considered individual must respect dignity recognize merit must sense security jobs compensation must fair adequate working conditions clean orderly safe must mindful ways help employees fulfill family responsibilities employees must feel free make suggestions complaints must equal opportunity employment development advancement qualified must provide competent management actions must ethical responsible communities live work world community well must good citizenssupport good works charities bear fair share taxes must encourage civic improvements better health education must maintain good order property privileged use protecting environment natural resources final responsibility stockholders business must make sound profit must experiment new ideas research must carried innovative programs developed mistakes paid new equipment must purchased new facilities provided new products launched reserves must created provide adverse times operate according principles stockholders realize fair return one johnson johnson plaza new brunswick new jersey